<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VALCYTE- valganciclovir hydrochloride tablet, film coated </strong><br><strong>VALCYTE- valganciclovir hydrochloride powder, for solution </strong><br>Genentech, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VALCYTE<span class="Sup">®</span> safely and effectively. See full prescribing information for VALCYTE. <br><br>VALCYTE (valganciclovir hydrochloride) tablets, <br>VALCYTE (valganciclovir hydrochloride) for oral solution <br>Initial U.S. Approval: 2001 </div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold">Hematologic Toxicity: Severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, bone marrow <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> have been reported in patients treated with VALCYTE (<a href="#S5.1">5.1</a>).</span></li>
<li><span class="Bold">Impairment of Fertility: Based on animal data, VALCYTE may cause temporary or permanent inhibition of spermatogenesis (<a href="#S5.2">5.2</a>).</span></li>
<li><span class="Bold">Fetal Toxicity: Based on animal data, VALCYTE has the potential to cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in humans (<a href="#S5.3">5.3</a>). </span></li>
<li><span class="Bold">Mutagenesis and Carcinogenesis: Based on animal data, VALCYTE has the potential to cause cancers in humans (<a href="#S5.4">5.4</a>). </span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table class="Noautorules" width="100%">
<col align="left" valign="top" width="85%">
<col align="right" valign="top" width="15%">
<tbody class="Headless">
<tr>
<td align="left"><ul><li>Indications and Usage, Pediatric Patients (<a href="#S1.2">1.2</a>)</li></ul></td>
<td align="right">04/2015</td>
</tr>
<tr>
<td align="left"><ul><li>Dosage and Administration, Pediatric Patients (<a href="#S2.3">2.3</a>)</li></ul></td>
<td align="right">04/2015</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold">Hematologic Toxicity: Severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, bone marrow <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> have been reported in patients treated with VALCYTE (<a href="#S5.1">5.1</a>).</span></li>
<li><span class="Bold">Impairment of Fertility: Based on animal data, VALCYTE may cause temporary or permanent inhibition of spermatogenesis (<a href="#S5.2">5.2</a>).</span></li>
<li><span class="Bold">Fetal Toxicity: Based on animal data, VALCYTE has the potential to cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in humans (<a href="#S5.3">5.3</a>). </span></li>
<li><span class="Bold">Mutagenesis and Carcinogenesis: Based on animal data, VALCYTE has the potential to cause cancers in humans (<a href="#S5.4">5.4</a>). </span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">VALCYTE is a cytomegalovirus (CMV) nucleoside analogue DNA polymerase inhibitor indicated for: </p>
<p class="Highlighta"><span class="Underline">Adult Patients</span> (<a href="#S1.1">1.1</a>) </p>
<ul>
<li>Treatment of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> in patients with <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span> (AIDS).</li>
<li>Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk.</li>
</ul>
<p class="Highlighta"><span class="Underline">Pediatric Patients</span> (<a href="#S1.2">1.2</a>)  </p>
<ul><li>Prevention of CMV disease in kidney and heart transplant patients at high risk.</li></ul>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<table width="100%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="70%">
<tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="2"><span class="Bold">Adult Dosage (<a href="#S2.2">2.2</a>)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Treatment of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span></td>
<td class="Rrule" align="left">Induction: 900 mg (two 450 mg tablets) twice a day for 21 days<br>Maintenance: 900 mg (two 450 mg tablets) once a day </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Prevention of CMV disease in heart or kidney-pancreas transplant patients</td>
<td class="Rrule" align="left">900 mg (two 450 mg tablets) once a day within 10 days of transplantation until 100 days post-transplantation</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Prevention of CMV disease in kidney transplant patients</td>
<td class="Rrule" align="left">900 mg (two 450 mg tablets) once a day within 10 days of transplantation until 200 days post-transplantation</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="2"><span class="Bold">Pediatric Dosage (<a href="#S2.3">2.3</a>)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Prevention of CMV disease in kidney transplant patients 4 months to 16 years of age</td>
<td class="Rrule" align="left">Dose once a day within 10 days of transplantation until 200 days post-transplantation according to dosage algorithm (note the calculation of creatinine clearance using a modified Schwartz formula in children)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Prevention of CMV disease in heart transplant patients 1 month to 16 years of age</td>
<td class="Rrule" align="left">Dose once a day within 10 days of transplantation until 100 days  post-transplantation according to dosage algorithm (note the calculation of creatinine clearance using a modified Schwartz formula in children)</td>
</tr>
</tbody>
</table>
<ul>
<li>VALCYTE for oral solution and tablets should be taken with food (<a href="#S2.1">2.1</a>, <a href="#S12.3">12.3</a>).</li>
<li>VALCYTE tablets should not be broken or crushed (<a href="#S2.6">2.6</a>). </li>
<li>Adult patients should use VALCYTE tablets, not VALCYTE for oral solution (<a href="#S2.1">2.1</a>).</li>
<li>Adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: Adjust dose based on creatinine clearance.  For adult patients receiving hemodialysis a dose recommendation cannot be given (<a href="#S2.5">2.5</a>, <a href="#S8.6">8.6</a>, <a href="#S12.3">12.3</a>). </li>
</ul>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul>
<li>Tablets: 450 mg (<a href="#S3">3</a>) </li>
<li>Oral Solution: 50 mg per mL (<a href="#S3">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to valganciclovir or ganciclovir (<a href="#S4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Hematologic toxicity: Severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> have occurred with the use of VALCYTE or ganciclovir. Avoid VALCYTE use if absolute neutrophil count is less than 500 cells/µL, platelet count is less than 25,000/µL, or hemoglobin is less than 8 g/dL. Use with caution in pre-existing <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> and when receiving myelosuppressive drugs or irradiation. Monitor with frequent testing of platelet and complete blood counts (<a href="#S5.1">5.1</a>).</li>
<li>Impairment of fertility: Based on animal studies, VALCYTE may cause temporary or permanent inhibition of spermatogenesis (<a href="#S5.2">5.2</a>).</li>
<li>Fetal toxicity: Based on animal studies, VALCYTE may cause fetal harm. Females of reproductive potential should use effective contraception during and following treatment and males should practice barrier contraception during and following treatment (<a href="#S5.3">5.3</a>).</li>
<li>Mutagenicity and carcinogenicity: Based on animal studies, VALCYTE is potentially mutagenic and carcinogenic (<a href="#S5.4">5.4</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span>: <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> may occur in elderly patients (with or without reduced renal function), patients who receive concomitant nephrotoxic drugs, or inadequately hydrated patients. Use with caution in elderly patients or those taking nephrotoxic drugs, reduce dosage in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and monitor renal function (<a href="#S2.5">2.5</a>, <a href="#S5.5">5.5</a>, <a href="#S8.5">8.5</a>, <a href="#S8.6">8.6</a>, <a href="#S12.3">12.3</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li>Adult patients: Most common adverse events and laboratory abnormalities (reported in at least one indication by greater than or equal to 20% of patients) are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">graft rejection</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (<a href="#S6.1">6.1</a>).</li>
<li>Pediatric patients: Most common adverse events and laboratory abnormalities (reported in greater than or equal to 20% of pediatric solid organ transplant recipients) are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (<a href="#S6.1">6.1</a>).</li>
</ul>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Zidovudine: Potential to cause <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Monitor with frequent tests of white blood cell counts with differential and hemoglobin levels (<a href="#S7">7</a>). </li>
<li>Probenecid: May increase ganciclovir levels. Monitor for evidence of ganciclovir toxicity (<a href="#S7">7</a>). </li>
<li>Mycophenolate mofetil (MMF): May increase ganciclovir concentrations and levels of MMF metabolites in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Monitor for ganciclovir and MMF toxicity (<a href="#S7">7</a>). </li>
<li>Didanosine: May increase didanosine concentrations. Monitor for didanosine toxicity (<a href="#S7">7</a>). </li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul><li>Lactation: Breastfeeding is not recommended with use of VALCYTE (<a href="#S8.2">8.2</a>).</li></ul></div>
<div>
<div></div>
<div><div></div></div>
<div><div></div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
</div>
</div>
<div><div></div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div>
<div><div></div></div>
<div><div></div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 4/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Adult Patients</a></h2>
<h2><a href="#section-1.2" class="toc">1.2	Pediatric Patients</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	General Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Recommended Dosage in Adult Patients with Normal Renal Function</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Recommended Dosage in Pediatric Patients</a></h2>
<h2><a href="#section-2.4" class="toc">2.4	Preparation of VALCYTE for Oral Solution </a></h2>
<h2><a href="#section-2.5" class="toc">2.5	Dosage Recommendation for Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.6" class="toc">2.6	Handling and Disposal</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Hematologic Toxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Impairment of Fertility</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Fetal Toxicity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Mutagenesis and Carcinogenesis</a></h2>
<h2><a href="#section-5.5" class="toc">5.5	<span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute Renal Failure</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience </a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2	Lactation</a></h2>
<h2><a href="#section-8.3" class="toc">8.3	Females and Males of Reproductive Potential </a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	Adult Patients</a></h2>
<h2><a href="#section-13.2" class="toc">14.2	Pediatric Patients</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS</span></h1>
<ul>
<li><span class="Bold">Hematologic Toxicity: Severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, bone marrow <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> have been reported in patients treated with VALCYTE <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>].</span></span></li>
<li><span class="Bold">Impairment of Fertility: Based on animal data, VALCYTE may cause temporary or permanent inhibition of spermatogenesis <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>].</span></span></li>
<li><span class="Bold">Fetal Toxicity: Based on animal data, VALCYTE has the potential to cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in humans <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>].</span></span></li>
<li><span class="Bold">Mutagenesis and Carcinogenesis: Based on animal data, VALCYTE has the potential to cause cancers in humans <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>].</span></span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Adult Patients</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1.1"></a><p></p>
<p class="First"><span class="Underline">Treatment of Cytomegalovirus (CMV) <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">Retinitis</span>:</span> VALCYTE is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> in patients with <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span> (AIDS) <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1.2"></a><p></p>
<p class="First"><span class="Underline">Prevention of CMV Disease:</span> VALCYTE is indicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]) <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	Pediatric Patients</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2.1"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Underline">Prevention of CMV Disease:</span> VALCYTE is indicated for the prevention of CMV disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk <span class="Italics">[see <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	General Dosing Information</h2>
<ul>
<li>Adult patients should use VALCYTE tablets, not VALCYTE for oral solution. </li>
<li>VALCYTE for oral solution and tablets should be taken with food <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. </li>
<li>VALCYTE for oral solution (50 mg/mL) must be prepared by the pharmacist prior to dispensing to the patient <span class="Italics">[see <a href="#S2.4">Dosage and Administration (2.4)</a>]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Recommended Dosage in Adult Patients with Normal Renal Function</h2>
<p class="First">For dosage recommendations in adult patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <span class="Italics"><a href="#S2.5">Dosage and Administration (2.5)</a>]</span>. </p>
<p><span class="Underline">Treatment of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span>:</span></p>
<ul>
<li>Induction: The recommended dosage is 900 mg (two 450 mg tablets) taken orally twice a day for 21 days. </li>
<li>Maintenance: Following induction treatment, or in adult patients with inactive <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>, the recommended dosage is 900 mg (two 450 mg tablets) taken orally once a day.</li>
</ul>
<p><span class="Underline">Prevention of CMV Disease:</span></p>
<ul>
<li>For adult patients who have received a heart or kidney-pancreas transplant, the recommended dosage is 900 mg (two 450 mg tablets) taken orally once a day starting within 10 days of transplantation until 100 days post-transplantation.</li>
<li>For adult patients who have received a kidney transplant, the recommended dosage is 900 mg (two 450 mg tablets) taken orally once a day starting within 10 days of transplantation until 200 days post-transplantation.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Recommended Dosage in Pediatric Patients</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.1"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Underline">Prevention of CMV Disease in Pediatric Kidney Transplant Patients:</span> For pediatric kidney transplant patients 4 months to 16 years of age, the recommended once daily mg dose (7× BSA × CrCL) should start within 10 days of post-transplantation until 200 days post-transplantation.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.2"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Underline">Prevention of CMV Disease in Pediatric Heart Transplant Patients</span>: For pediatric heart transplant patients 1 month to 16 years of age, the recommended once daily mg dose (7× BSA × CrCL) should start within 10 days of transplantation until 100 days post-transplantation.</span></p>
<p>The recommended once daily dosage of VALCYTE is based on body surface area (BSA) and creatinine clearance (CrCl) derived from a modified Schwartz formula, and is calculated using the equation below:</p>
<p>Pediatric Dose (mg) = 7 × BSA × CrCl (calculated using a modified Schwartz formula). If the calculated Schwartz creatinine clearance exceeds 150 mL/min/1.73m<span class="Sup">2</span>, then a maximum value of 150 mL/min/1.73m<span class="Sup">2</span> should be used in the equation. The k values used in the modified Schwartz formula are based on pediatric patient age, as shown in <span class="Bold"><a href="#table1">Table 1</a></span>.</p>
<div class="Figure"><img alt="Math Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dc548ff9-e8ea-4d6e-b9b4-e31f53ac4078&amp;name=valcyte-01.jpg"></div>
<a name="table1"></a><table width="75%">
<caption><span>Table 1. 	k Values According to Pediatric Patient Age<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="85%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">k value</th>
<th class="Rrule" align="left">Pediatric Patient Age</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd><span class="XmChange">The k values provided are based on the Jaffe method of measuring serum creatinine, and may require correction when enzymatic methods are used<span class="Sup">1</span>.</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">0.33</td>
<td class="Rrule" align="left">Infants less than 1 year of age with low birth weight for gestational age</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">0.45</td>
<td class="Rrule" align="left">Infants less than 1 year of age with birth weight appropriate for gestational age</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">0.45</td>
<td class="Rrule" align="left">Children aged 1 to less than 2 years </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">0.55</td>
<td class="Rrule" align="left">Boys aged 2 to less than 13 years<br>Girls aged 2 to less than 16 years</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">0.7</td>
<td class="Rrule" align="left">Boys aged 13 to 16 years</td>
</tr>
</tbody>
</table>
<p style="border-left:1px solid;"><span class="XmChange">Monitor serum creatinine levels regularly and consider changes in height and body weight and adapt the dose as appropriate during prophylaxis period. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">All calculated doses should be rounded to the nearest 10 mg increment for the actual deliverable dose. If the calculated dose exceeds 900 mg, a maximum dose of 900 mg should be administered. VALCYTE for oral solution is the preferred formulation since it provides the ability to administer a dose calculated according to the formula above; however, VALCYTE tablets may be used if the calculated doses are within 10% of available tablet strength (450 mg). For example, if the calculated dose is between 405 mg and 495 mg, one 450 mg tablet may be taken. Before prescribing VALCYTE tablets, pediatric patients should be assessed for the ability to swallow tablets.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	Preparation of VALCYTE for Oral Solution </h2>
<p class="First">Prior to dispensing to the patient, VALCYTE for oral solution must be prepared by the pharmacist as follows <span class="Italics">[see <a href="#S16">How Supplied/Storage and Handling (16)</a>]</span>:</p>
<ul>
<li>Measure 91 mL of purified water in a graduated cylinder.</li>
<li>Shake the VALCYTE bottle to loosen the powder. Remove the child resistant bottle cap and add approximately half the total amount of water for constitution to the bottle and shake the closed bottle well for about 1 minute. Add the remainder of water and shake the closed bottle well for about 1 minute. This prepared solution contains 50 mg of valganciclovir free base per 1 mL.</li>
<li>Remove the child resistant bottle cap and push the bottle adapter into the neck of the bottle.</li>
<li>Close bottle with child resistant bottle cap tightly. This will assure the proper seating of the bottle adapter in the bottle and child resistant status of the cap.</li>
<li>Store constituted oral solution under refrigeration at 2°C to 8°C (36°F to 46°F) for no longer than 49 days. Do not freeze. </li>
<li>Write the date of expiration of the constituted oral solution on the bottle label.</li>
</ul>
<p>The patient package insert, which includes the dosing instructions for patients, and 2 oral dispensers should be dispensed to the patient <span class="Italics">[see <a href="#S17">Patient Counseling Information (17)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5	Dosage Recommendation for Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Serum creatinine levels or creatinine clearance should be monitored regularly during treatment.  Dosage recommendations for adult patients with reduced renal function are provided in <span class="Bold"><a href="#table2">Table 2</a></span>. For adult patients on hemodialysis (CrCl less than 10 mL/min), a dose recommendation for VALCYTE cannot be given <span class="Italics">[see <a href="#S8.5">Use in Specific Populations (8.5</a>, <a href="#S8.6">8.6)</a>, <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2	Dosage Recommendations for Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span></caption>
<col align="center" valign="middle" width="34%">
<col align="center" valign="middle" width="34%">
<col align="center" valign="middle" width="32%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="3">VALCYTE 450 mg Tablets</th></tr>
<tr class="Last">
<th class="Lrule Rrule" align="center" valign="middle">CrCl<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> (mL/min)</th>
<th class="Rrule" align="center" valign="middle">Induction Dose</th>
<th class="Rrule" align="center" valign="middle">Maintenance/Prevention Dose</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>An estimated creatinine clearance in adults is calculated from serum creatinine by the following formulas:<br><br>                         (140 – age [years]) × (body weight [kg])<br>For males =      —————————————————<br>                         (72) × (serum creatinine [mg/dL])<br><br>For females = 0.85 × male value</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="center">≥ 60</td>
<td class="Rrule" align="center">900 mg twice daily</td>
<td class="Rrule" align="center">900 mg once daily</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">40 – 59</td>
<td class="Rrule Toprule" align="center">450 mg twice daily</td>
<td class="Rrule Toprule" align="center">450 mg once daily</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">25 – 39</td>
<td class="Rrule Toprule" align="center">450 mg once daily</td>
<td class="Rrule Toprule" align="center">450 mg every 2 days</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">10 – 24</td>
<td class="Rrule Toprule" align="center">450 mg every 2 days</td>
<td class="Rrule Toprule" align="center">450 mg twice weekly</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="center">&lt; 10<br>(on hemodialysis)</td>
<td class="Rrule Toprule" align="center" valign="middle">not recommended</td>
<td class="Rrule Toprule" align="center" valign="middle">not recommended</td>
</tr>
</tbody>
</table>
<p>	Dosing in pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> can be done using the recommended equations because CrCl is a component in the calculation <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.6"></a><a name="section-2.6"></a><p></p>
<h2>2.6	Handling and Disposal</h2>
<p class="First">Caution should be exercised in the handling of VALCYTE tablets and VALCYTE for oral solution. Tablets should not be broken or crushed. Because valganciclovir is considered a potential teratogen and carcinogen in humans, caution should be observed in handling broken tablets, the powder for oral solution, and the constituted oral solution <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3</a>, <a href="#S5.4">5.4)</a>]</span>. Avoid direct contact with broken or crushed tablets, the powder for oral solution, and the constituted oral solution with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, and rinse eyes thoroughly with plain water.</p>
<p>Handle and dispose VALCYTE according to guidelines for antineoplastic drugs because ganciclovir shares some of the properties of antitumor agents (i.e., carcinogenicity and mutagenicity)<span class="Sup">2</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul>
<li>VALCYTE tablets: 450 mg, pink, convex oval tablets with "VGC" on one side and "450" on the other side.</li>
<li>VALCYTE for oral solution: 50 mg per mL, supplied as a white to slightly yellow powder for constitution, forming a colorless to brownish yellow tutti-frutti flavored solution. Available in glass bottles containing approximately 100 mL of solution after constitution.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">VALCYTE is contraindicated in patients who have had a demonstrated clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to valganciclovir, ganciclovir, or any component of the formulation <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Hematologic Toxicity</h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, bone marrow <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span>, and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> have been reported in patients treated with VALCYTE or ganciclovir. VALCYTE should be avoided if the absolute neutrophil count is less than 500 cells/µL, the platelet count is less than 25,000/µL, or the hemoglobin is less than 8 g/dL. VALCYTE should also be used with caution in patients with pre-existing <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span>, or who have received or who are receiving myelosuppressive drugs or irradiation. <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenia</span> may occur at any time during treatment and may worsen with continued dosing. Cell counts usually begin to recover within 3 to 7 days after discontinuing drug. </p>
<p>Due to the frequency of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in patients receiving VALCYTE <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>, complete blood counts with differential and platelet counts should be performed frequently, especially in patients in whom ganciclovir or other nucleoside analogues have previously resulted in <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, or in whom neutrophil counts are less than 1000 cells/µL at the beginning of treatment. Increased monitoring for <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> may be warranted if therapy with oral ganciclovir is changed to VALCYTE, because of increased plasma concentrations of ganciclovir after VALCYTE administration <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Impairment of Fertility</h2>
<p class="First">Based on animal data with ganciclovir, VALCYTE at the recommended human doses may cause temporary or permanent inhibition of spermatogenesis in males, and may cause suppression of fertility in females. Advise patients that fertility may be impaired with use of VALCYTE <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1</a>, <a href="#S8.3">8.3)</a>, <a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Fetal Toxicity</h2>
<p class="First">	Ganciclovir may cause fetal toxicity when administered to pregnant women based on findings in animal studies. When given to pregnant rabbits at dosages resulting in 2-times the human exposure (based on AUC), ganciclovir caused malformations in multiple organs of the fetuses. Maternal and fetal toxicity were also observed in pregnant mice and rabbits. Therefore, VALCYTE has the potential to cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. Pregnancy should be avoided in female patients taking VALCYTE and in females with male partners taking VALCYTE. Females of reproductive  potential should be advised to use effective contraception during treatment and for at least 30 days following treatment with VALCYTE. Similarly, males should be advised to practice barrier contraception during and for at least 90 days following treatment with VALCYTE <span class="Italics">[see <a href="#S2.6">Dosage and Administration (2.6)</a>, <a href="#S8.1">Use in Specific Populations (8.1</a>, <a href="#S8.3">8.3)</a>, <a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Mutagenesis and Carcinogenesis</h2>
<p class="First">Animal data indicate that ganciclovir is mutagenic and carcinogenic. VALCYTE should therefore be considered a potential carcinogen in humans <span class="Italics">[see <a href="#S2.6">Dosage and Administration (2.6)</a>, <a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	<span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute Renal Failure</span></h2>
<p class="First">	<span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> may occur in:</p>
<ul>
<li>Elderly patients with or without reduced renal function. Caution should be exercised when administering VALCYTE to geriatric patients, and dosage reduction is recommended for those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a>, <a href="#S8.5">Use in Specific Populations (8.5</a>, <a href="#S8.6">8.6)</a>]</span>.</li>
<li>Patients receiving potential nephrotoxic drugs. Caution should be exercised when administering VALCYTE to patients receiving potential nephrotoxic drugs.</li>
<li>Patients without adequate hydration. Adequate hydration should be maintained for all patients.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse events are discussed in greater detail in other sections of the labeling:</p>
<ul>
<li>Hematologic toxicity <span class="Italics">[see <a href="#BOX">Boxed Warning</a>, <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>.</li>
</ul>
<p>The most common adverse events and laboratory abnormalities reported in at least one indication by greater than or equal to 20% of adult patients treated with VALCYTE tablets are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">graft rejection</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. The most common reported adverse events and laboratory abnormalities reported in greater than or equal to 20% of pediatric solid organ transplant recipients treated with VALCYTE for oral solution or tablets are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in practice.</p>
<p>Valganciclovir, a prodrug of ganciclovir, is rapidly converted to ganciclovir after oral administration. Adverse events known to be associated with ganciclovir usage can therefore be expected to occur with VALCYTE.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Adverse Events in Adults:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Treatment of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span> in AIDS Patients:</span> In a clinical study for the treatment of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> in HIV-infected patients, the adverse events reported by patients receiving VALCYTE tablets (n=79) or intravenous ganciclovir (n=79) for 28 days of randomized therapy (21 days induction dose and 7 days maintenance dose), respectively, included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (16%, 10%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (8%, 14%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (9%, 5%), and catheter-related <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (3%, 11%). The incidence of adverse events was similar between the group who received VALCYTE tablets and the group who received intravenous ganciclovir, with the exception of catheter-related <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, which occurred with greater frequency in patients randomized to receive intravenous ganciclovir. The frequencies of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (ANC less than 500/µL) were 11% for patients receiving VALCYTE tablets compared with 13% for patients receiving intravenous ganciclovir. <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (Hgb less than 8 g/dL) occurred in 8% of patients in each group. Other laboratory abnormalities occurred with similar frequencies in the two groups.</p>
<p>Adverse events and abnormal laboratory values data are available for 370 patients who received maintenance therapy with VALCYTE tablets 900 mg once daily in two open-label clinical trials. Approximately 252 (68%) of these patients received VALCYTE tablets for more than nine months (maximum duration was 36 months). <span class="Bold"><a href="#table3">Table 3</a></span> and <span class="Bold"><a href="#table4">Table 4</a></span> show the pooled adverse event data and abnormal laboratory values from these patients.</p>
<a name="table3"></a><table width="75%">
<caption><span>Table 3	Pooled Selected Adverse Events Reported in greater than or equal to 5% of Patients who Received VALCYTE Tablets Maintenance Therapy for <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span></span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="top" width="50%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Patients with <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span></th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">Adverse Events According to Body System</th>
<th class="Rrule Toprule" align="center">VALCYTE Tablets<br>(N=370)<br>%</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold">Gastrointestinal system</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">41</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">30</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">21</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Rrule" align="center">15</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">Body as a whole </span></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">31</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">22</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">Central and peripheral nervous system</span></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">16</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span></td>
<td class="Rrule" align="center">9</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Rrule" align="center">8</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">Special senses</span></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">Retinal detachment</span></td>
<td class="Rrule" align="center">15</td>
</tr>
</tbody>
</table>
<a name="table4"></a><table width="75%">
<caption><span>Table 4	Pooled Laboratory Abnormalities Reported in Patients Who Received VALCYTE Tablets Maintenance Therapy for the Treatment of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span></span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Patients with <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span></th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">Laboratory Abnormalities</th>
<th class="Rrule Toprule" align="center">VALCYTE Tablets<br>(N=370)<br>%</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>: ANC/µL</td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  &lt; 500</td>
<td class="Rrule" align="center">19</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  500 – &lt; 750</td>
<td class="Rrule" align="center">17</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  750 – &lt; 1000</td>
<td class="Rrule" align="center">17</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>: Hemoglobin g/dL</td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  &lt; 6.5</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  6.5 – &lt; 8.0</td>
<td class="Rrule" align="center">13</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  8.0 – &lt; 9.5</td>
<td class="Rrule" align="center">16</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>: Platelets/µL</td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  &lt; 25000</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  25000 – &lt; 50000</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  50000 – &lt; 100000</td>
<td class="Rrule" align="center">22</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Serum Creatinine: mg/dL</td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  &gt; 2.5</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  &gt; 1.5 – 2.5</td>
<td class="Rrule" align="center">12</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.2"></a><p></p>
<p class="First"><span class="Italics">Prevention of CMV Disease in Selected Solid Organ Transplantation:</span> <span class="Bold"><a href="#table5">Table 5</a></span> shows selected adverse events regardless of severity and drug relationship with an incidence of greater than or equal to 5% from a clinical trial (up to 28 days after study treatment) where heart, kidney, kidney-pancreas and liver transplant patients received VALCYTE tablets (N=244) or oral ganciclovir (N=126) until Day 100 post-transplant. The majority of the adverse events were of mild or moderate intensity. </p>
<a name="table5"></a><table width="80%">
<caption><span>Table 5	Percentage of Selected Grades 1-4 Adverse Events Reported in greater than or equal to 5% of Adult Patients From a Study of Solid Organ Transplant Patients</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="middle">Adverse Event</th>
<th class="Rrule" align="center">VALCYTE Tablets<br>(N=244)<br>%</th>
<th class="Rrule" align="center">Oral Ganciclovir<br>(N=126)<br>%</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">30</td>
<td class="Rrule" align="center">29</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremors</span></td>
<td class="Rrule Toprule" align="center">28</td>
<td class="Rrule Toprule" align="center">25</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">Graft rejection</span></td>
<td class="Rrule Toprule" align="center">24</td>
<td class="Rrule Toprule" align="center">30</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule Toprule" align="center">23</td>
<td class="Rrule Toprule" align="center">23</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule Toprule" align="center">22</td>
<td class="Rrule Toprule" align="center">27</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule Toprule" align="center">20</td>
<td class="Rrule Toprule" align="center">16</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule Toprule" align="center">18</td>
<td class="Rrule Toprule" align="center">15</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule Toprule" align="center">16</td>
<td class="Rrule Toprule" align="center">14</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule Toprule" align="center">13</td>
<td class="Rrule Toprule" align="center">14</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><a href="#table6">Table 6</a></span> shows selected adverse events regardless of severity and drug relationship with an incidence of greater than or equal to 5% from another clinical trial where kidney transplant patients received either valganciclovir once daily starting within 10 days post-transplant until Day 100 post-transplant followed by 100 days of placebo or valganciclovir once daily starting within 10 days post-transplant until Day 200 post-transplant. The overall safety profile of VALCYTE did not change with the extension of prophylaxis until Day 200 post-transplant in high risk kidney transplant patients.</p>
<a name="table6"></a><table width="80%">
<caption><span>Table 6	Percentage of Selected Grades 1-4 Adverse Events Reported in greater than or equal to 5% of Adult Patients from a Study of Kidney Transplant Patients</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="middle">Adverse Event</th>
<th class="Rrule" align="center">VALCYTE Tablets Day 100 Post-transplant<br>(N=164)<br>%</th>
<th class="Rrule" align="center">VALCYTE Tablets Day 200 Post-transplant<br>(N=156)<br>%</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">31</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremors</span></td>
<td class="Rrule Toprule" align="center">12</td>
<td class="Rrule Toprule" align="center">17</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule Toprule" align="center">13</td>
<td class="Rrule Toprule" align="center">12</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule Toprule" align="center">11</td>
<td class="Rrule Toprule" align="center">11</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule Toprule" align="center">12</td>
<td class="Rrule Toprule" align="center">9</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">Transplant rejection</span></td>
<td class="Rrule Toprule" align="center">9</td>
<td class="Rrule Toprule" align="center">6</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule Toprule" align="center">10</td>
<td class="Rrule Toprule" align="center">6</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule Toprule" align="center">7</td>
<td class="Rrule Toprule" align="center">6</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule Toprule" align="center">3</td>
<td class="Rrule Toprule" align="center">6</td>
</tr>
</tbody>
</table>
<p>Adverse events not included in <span class="Bold"><a href="#table5">Table 5</a></span> and <span class="Bold"><a href="#table6">Table 6</a></span>, which either occurred at a frequency of greater than or equal to 5% in clinical studies with solid organ transplant patients, or were selected serious adverse events reported in studies with patients with <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> or in studies with solid organ transplant patients with a frequency of less than 5% are listed below.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>:</span> valganciclovir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> complications:</span> potentially life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p><span class="Italics">Central and peripheral nervous system:</span> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (excluding <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span></p>
<p><span class="Italics">General disorders and administration site disorders:</span> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></p>
<p><span class="Italics">Hemic system:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span></p>
<p><span class="Italics">Hepatobiliary disorders:</span> abnormal hepatic function </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>:</span> <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, local and systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="4237450" conceptname="Postoperative wound infection">postoperative wound infection</span></p>
<p><span class="Italics">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, and procedural complications:</span> postoperative complications, <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>, increased <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> drainage, <span class="product-label-link" type="condition" conceptid="439981" conceptname="Wound dehiscence">wound dehiscence</span></p>
<p><span class="Italics">Metabolism and nutrition disorders:</span> <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">appetite decreased</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span></p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, limb <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> </p>
<p><span class="Italics">Psychiatric disorders:</span> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span></p>
<p><span class="Italics">Renal and urinary disorders:</span> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, decreased creatinine clearance</p>
<p><span class="Italics">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span></p>
<p><span class="Italics">Skin and subcutaneous tissue disorders:</span> <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></p>
<p>Laboratory abnormalities reported with VALCYTE tablets in two studies in adult solid organ transplant patients are listed in <span class="Bold"><a href="#table7">Table 7</a></span> and <span class="Bold"><a href="#table8">Table 8</a></span>. </p>
<a name="table7"></a><table width="85%">
<caption><span>Table 7	Selected Laboratory Abnormalities Reported in a Study of Adult Solid Organ Transplant Patients<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="middle">Laboratory Abnormalities</th>
<th class="Rrule" align="center">VALCYTE Tablets<br>(N=244)<br>%</th>
<th class="Rrule" align="center">Ganciclovir Capsules<br>(N=126)<br>%</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Laboratory abnormalities are those reported by investigators.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>: ANC/µL</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  &lt; 500</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  500 – &lt; 750</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  750 – &lt; 1000</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>: Hemoglobin g/dL</td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  &lt; 6.5</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  6.5 – &lt; 8.0</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  8.0 – &lt; 9.5</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">25</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>: Platelets/µL</td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  &lt; 25000</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  25000 – &lt; 50000</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  50000 – &lt; 100000</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">21</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Serum Creatinine: mg/dL</td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  &gt; 2.5</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">21</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  &gt; 1.5 – 2.5</td>
<td class="Rrule" align="center">45</td>
<td class="Rrule" align="center">47</td>
</tr>
</tbody>
</table>
<a name="table8"></a><table width="85%">
<caption><span>Table 8	Selected Laboratory Abnormalities Reported in a Study of Adult Kidney Transplant Patients<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="middle">Laboratory Abnormalities</th>
<th class="Rrule" align="center">VALCYTE Tablets Day 100 Post-transplant<br>(N=164)<br>%</th>
<th class="Rrule" align="center">VALCYTE Tablets Day 200 Post-transplant<br>(N=156)<br>%</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Laboratory abnormalities are those reported by investigators.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>: ANC/µL</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  &lt; 500</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  500 – &lt; 750</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  750 – &lt; 1000</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>: Hemoglobin g/dL</td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  &lt; 6.5</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  6.5 – &lt; 8.0</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  8.0 – &lt; 9.5</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">15</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>: Platelets/µL</td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  &lt; 25000</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  25000 – &lt; 50000</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  50000 – &lt; 100000</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Serum Creatinine: mg/dL</td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  &gt; 2.5</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">14</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  &gt; 1.5 – 2.5</td>
<td class="Rrule" align="center">50</td>
<td class="Rrule" align="center">48</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline">Adverse Events in Pediatric Patients:</span></p>
<p>VALCYTE for oral solution and tablets have been studied in 179 pediatric solid organ transplant patients who were at risk for developing CMV disease (aged 3 weeks to 16 years) and in 24 neonates with symptomatic congenital CMV disease (aged 8 to 34 days), with duration of ganciclovir exposure ranging from 2 to 200 days <span class="Italics">[see <a href="#S8.4">Use in Specific Populations (8.4)</a>, <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2.1"></a><p></p>
<p class="First"><span class="Italics">Prevention of CMV Disease in Pediatric Solid Organ Transplant Patients:</span> The most frequently reported adverse events (greater than 10% of patients), regardless of seriousness and drug relationship in pediatric solid organ transplant patients taking VALCYTE until Day 100 post-transplant were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">transplant rejection</span>. The most frequently reported adverse events (greater than 10% of patients), in pediatric kidney transplant patients treated with valganciclovir until Day 200 post-transplant were <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, blood creatinine increase, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="Italics">E. coli</span> <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>. </p>
<p>In general, the safety profile was similar in pediatric patients compared to that observed in adult patients. However, the rates of certain adverse events and laboratory abnormalities, such as <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> were reported more frequently in pediatric patients than in adults <span class="Italics">[see <a href="#S8.4">Use in Specific Populations (8.4)</a>, <a href="#S14.2">Clinical Studies (14.2)</a>].</span>  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> was reported with higher incidence in the two pediatric studies as compared to adults, but there was no correlation between <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> observed in the pediatric population.</p>
<p>The overall safety profile of VALCYTE was similar with the extension of prophylaxis until Day 200 post-transplant in high risk pediatric kidney transplant patients. However, the incidence of severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (ANC&lt;500/µL) was higher in pediatric kidney transplant patients treated with VALCYTE until Day 200 (17/57, 30%) compared to pediatric kidney transplant patients treated until Day 100 (3/63, 5%). There were no differences in the incidence of severe (Grade 4) <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in patients treated 100 or 200 days with VALCYTE.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience </h2>
<p class="First">The following adverse events have been identified during post-approval use of VALCYTE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.  As VALCYTE is rapidly and extensively converted to ganciclovir, any adverse events associated with ganciclovir might also occur with valganciclovir.</p>
<dl>
<dt>–</dt>
<dd><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></dd>
<dt>–</dt>
<dd>Decreased fertility in males</dd>
</dl>
<p>In general, the adverse events reported during the postmarketing use of VALCYTE were similar to those identified during the clinical trials.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">In vivo drug-drug interaction studies were not conducted with valganciclovir. However, because valganciclovir is rapidly and extensively converted to ganciclovir, drug-drug interactions associated with ganciclovir will be expected for VALCYTE. Established and other potentially significant drug interactions conducted with ganciclovir are listed in <span class="Bold"><a href="#table9">Table 9</a></span>.</p>
<a name="table9"></a><table width="85%">
<caption><span>Table 9	Established and Other Potentially Significant Drug Interactions with Ganciclovir</span></caption>
<col align="left" valign="top" width="28%">
<col align="left" valign="top" width="41%">
<col align="left" valign="top" width="31%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Name of the Concomitant Drug</th>
<th class="Rrule" align="center">Change in the Concentration of Ganciclovir or Concomitant Drug</th>
<th class="Rrule" align="center">Clinical Comment</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">Zidovudine</td>
<td class="Rrule" align="left">↓ Ganciclovir<br>↑ Zidovudine</td>
<td class="Rrule" align="left">Zidovudine and VALCYTE each have the potential to cause <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Probenecid</td>
<td class="Rrule Toprule" align="left">↑ Ganciclovir</td>
<td class="Rrule Toprule" align="left">Patients taking probenecid and VALCYTE should be monitored for evidence of ganciclovir toxicity</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Mycophenolate Mofetil (MMF)</td>
<td class="Rrule Toprule" align="left">↔ Ganciclovir (in patients with normal renal function)<br>↔ MMF (in patients with normal renal function)</td>
<td class="Rrule Toprule" align="left">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should be monitored carefully as levels of MMF metabolites and ganciclovir may increase</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left">Didanosine</td>
<td class="Rrule Toprule" align="left">↓ Ganciclovir<br>↑ Didanosine</td>
<td class="Rrule Toprule" align="left">Patients should be closely monitored for didanosine toxicity</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Underline">Risk Summary</span></p>
<p>After oral administration, valganciclovir (prodrug) is converted to ganciclovir (active drug) and, therefore, VALCYTE is expected to have reproductive toxicity effects similar to ganciclovir. In animal studies, ganciclovir caused maternal and fetal toxicity and embryo-fetal mortality in pregnant mice and rabbits as well as <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in rabbits at exposures two-times the human exposure. There are no available human data on use of VALCYTE or ganciclovir in pregnant women to establish the presence or absence of drug-associated risk. The background risk of major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> for the indicated populations is unknown. However, the background risk in the U.S. general population of major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> is 2-4% and the risk of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> is 15-20% of clinically recognized pregnancies. Advise pregnant women of the potential risk to the fetus <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>, <a href="#S8.3">Use in Specific Populations (8.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Underline">Clinical Considerations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2.1"></a><p></p>
<p class="First"><span class="Italics">Disease-associated maternal and/or embryo/fetal risk</span></p>
<p>Most maternal <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infections</span> are asymptomatic or they may be associated with a self-limited mononucleosis-like syndrome. However, in immunocompromised patients (i.e., transplant patients or patients with AIDS) <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infections</span> may be symptomatic and may result in significant maternal morbidity and mortality.  The transmission of CMV to the fetus is a result of maternal <span class="product-label-link" type="condition" conceptid="133327" conceptname="Viremia">viremia</span> and transplacental <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Perinatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> can also occur from exposure of the neonate to CMV shedding in the genital tract. Approximately 10% of children with <span class="product-label-link" type="condition" conceptid="436532" conceptname="Congenital cytomegalovirus infection">congenital CMV infection</span> are symptomatic at birth. Mortality in these infants is about 10% and approximately 50-90% of symptomatic surviving newborns experience significant morbidity, including <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental retardation</span>, <span class="product-label-link" type="condition" conceptid="374366" conceptname="Sensorineural hearing loss">sensorineural hearing loss</span>, <span class="product-label-link" type="condition" conceptid="381114" conceptname="Microcephalus">microcephaly</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and other medical problems. The risk of <span class="product-label-link" type="condition" conceptid="436532" conceptname="Congenital cytomegalovirus infection">congenital CMV infection</span> resulting from primary maternal <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span> may be higher and of greater severity than that resulting from maternal reactivation of <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span>.   </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.3"></a><p></p>
<p class="First"><span class="Underline">Data</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.3.1"></a><p></p>
<p class="First"><span class="Italics">Animal Data</span></p>
<p>At doses resulting in two-times the human exposure of ganciclovir (all dose comparisons presented are based on the human AUC following a single intravenous infusion of 5 mg per kg of ganciclovir) resulted in maternal and embryofetal toxicity in pregnant mice and rabbits as well as <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in the rabbits. Fetal resorptions were present in at least 85% of rabbits and mice. Rabbits showed increased embryofetal mortality, <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> of the fetuses and structural abnormalities of multiple organs of the fetuses including the palate (<span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>), eyes (<span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span>/<span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>), brain (<span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephalus</span>), jaw (brachygnathia), kidneys and pancreas (aplastic organs). Increased embryofetal mortality was also seen in mice. Daily intravenous doses of approximately 1.7-times the human exposure (based on AUC) administered to female mice prior to mating, during gestation, and during lactation caused hypoplasia of the testes and seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> in the male offspring, as well as pathologic changes in the nonglandular region of the stomach. </p>
<p>Data from an ex-vivo human placental model showed that ganciclovir crosses the human placenta. The transfer occurred by passive diffusion and was not saturable over a concentration range of 1 to 10 mg/mL.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="77290-5">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2	Lactation</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2.1"></a><p></p>
<p class="First"><span class="Underline">Risk Summary</span></p>
<p>No data are available regarding the presence of  valganciclovir (prodrug) or ganciclovir (active drug) in human milk, the effects on the breastfed infant, or the effects on milk production. The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV.  Advise nursing mothers that breastfeeding is not recommended during treatment with VALCYTE because of the potential for serious adverse events in nursing infants and because of the potential for transmission of HIV <span class="Italics">[see <a href="#BOX">Boxed Warning</a>, <a href="#S5.1">Warnings and Precautions (5.1</a>, <a href="#S5.2">5.2</a>, <a href="#S5.3">5.3</a>, <a href="#S5.4">5.4)</a>, <a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="77291-3">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3	Females and Males of Reproductive Potential </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.1"></a><p></p>
<p class="First"><span class="Underline">Pregnancy Testing</span></p>
<p>	Females of reproductive potential should undergo pregnancy testing before initiation of VALCYTE <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.2"></a><p></p>
<p class="First"><span class="Underline">Contraception</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.2.1"></a><p></p>
<p class="First"><span class="Underline">Females</span></p>
<p>Because of the mutagenic and teratogenic potential of VALCYTE, females of reproductive  potential should be advised to use effective contraception during treatment and for at least 30 days following treatment with VALCYTE <span class="Italics">[see <a href="#S2.6">Dosage and Administration (2.6)</a>, <a href="#S5.3">Warnings and Precautions (5.3</a>, <a href="#S5.4">5.4)</a>,  <a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.2.2"></a><p></p>
<p class="First"><span class="Underline">Males</span></p>
<p>Because of its mutagenic potential, males should be advised to practice barrier contraception during and for at least 90 days following, treatment with VALCYTE <span class="Italics">[see <a href="#S2.6">Dosage and Administration (2.6)</a>, <a href="#S5.3">Warnings and Precautions (5.3)</a>, <a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span></span></p>
<p>VALCYTE at the recommended doses may cause temporary or permanent female and male <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>, <a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">VALCYTE for oral solution and tablets are indicated for the prevention of CMV disease in pediatric patients 4 months to 16 years of age and in pediatric heart transplant patients 1 month to 16 years of age at risk for developing CMV disease <span class="Italics">[see <a href="#S1.2">Indications and Usage (1.2)</a>, <a href="#S2.3">Dosage and Administration (2.3)</a>].</span></p>
<p>The use of VALCYTE for oral solution and tablets for the prevention of CMV disease in pediatric kidney transplant patients 4 months to 16 years of age is based on two single-arm, open-label, non-comparative studies in patients 4 months to 16 years of age. Study 1 was a safety and pharmacokinetic study in pediatric solid organ transplant patients (kidney, liver, heart, and kidney/pancreas). VALCYTE was administered once daily within 10 days of transplantation for a maximum of 100 days post-transplantation. Study 2 was a safety and tolerability study where VALCYTE was administered once daily within 10 days of transplantation for a maximum of 200 days post-transplantation in pediatric kidney transplant patients. The results of these studies were supported by previous demonstration of efficacy in adult patients <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>, <a href="#S12.3">Clinical Pharmacology (12.3)</a>, <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>
<p>The use of VALCYTE for oral solution and tablets for the prevention of CMV disease in pediatric heart transplant patients 1 month to 16 years of age is based on two studies (Study 1 described above and Study 3) and was supported by previous demonstration of efficacy in adult patients <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>, <a href="#S14.2">Clinical Studies (14.2)</a>]</span>. Study 3 was a pharmacokinetic and safety study of VALCYTE in pediatric heart transplant patients less than 4 months of age who received a single dose of VALCYTE oral solution on each of two consecutive days. A physiologically based pharmacokinetic (PBPK) model was developed based on the available pharmacokinetic data from pediatric and adult patients to support dosing in heart transplant patients less than 1 month of age. However, due to uncertainty in model predictions for neonates, VALCYTE is not indicated for prophylaxis in this age group.</p>
<p>	The safety and efficacy of VALCYTE for oral solution and tablets have not been established in children for prevention of CMV disease in pediatric liver transplant patients, in kidney transplant patients less than 4 months of age, in heart transplant patients less than 1 month of age, in pediatric AIDS patients with <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>, and in infants with <span class="product-label-link" type="condition" conceptid="436532" conceptname="Congenital cytomegalovirus infection">congenital CMV infection</span>.</p>
<p>A pharmacokinetic and pharmacodynamic evaluation of VALCYTE for oral solution was performed in 24 neonates with <span class="product-label-link" type="condition" conceptid="436532" conceptname="Congenital cytomegalovirus infection">congenital CMV infection</span> involving the central nervous system. All patients were treated for 6 weeks with a combination of intravenous ganciclovir 6 mg per kg twice daily or VALCYTE for oral solution at doses ranging from 14 mg per kg to 20 mg per kg twice daily. The pharmacokinetic results showed that in infants greater than 7 days to 3 months of age, a dose of 16 mg per kg twice daily of VALCYTE for oral solution provided ganciclovir systemic exposures (median AUC<span class="Sub">0-12h</span> = 23.6 [range 16.8 – 35.5] mcg<span class="Bold">∙</span>h/mL; n = 6) comparable to those obtained in infants up to 3 months of age from a 6 mg per kg dose of intravenous ganciclovir twice daily (AUC<span class="Sub">0-12h</span> = 25.3 [range 2.4 – 89.7] mcg<span class="Bold">∙</span>h/mL; n = 18) or to the ganciclovir systemic exposures obtained in adults from a 900 mg dose of VALCYTE tablets twice daily. However, the efficacy and safety of intravenous ganciclovir and of VALCYTE have not been established for the treatment of <span class="product-label-link" type="condition" conceptid="436532" conceptname="Congenital cytomegalovirus infection">congenital CMV infection</span> in infants and no similar disease occurs in adults; therefore, efficacy cannot be extrapolated from intravenous ganciclovir use in adults.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Studies of VALCYTE for oral solution or tablets have not been conducted in adults older than 65 years of age. Clinical studies of VALCYTE did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. VALCYTE is known to be substantially excreted by the kidneys, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection. In addition, renal function should be monitored and dosage adjustments should be made accordingly <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a>, <a href="#S5.5">Warnings and Precautions (5.5)</a>, <a href="#S8.6">Use in Specific Populations (8.6)</a>, <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Dose reduction is recommended when administering VALCYTE to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a>, <a href="#S5.5">Warnings and Precautions (5.5)</a>, <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>For adult patients on hemodialysis (CrCl less than 10 mL/min) VALCYTE tablets should not be used. Adult hemodialysis patients should use ganciclovir in accordance with the dose-reduction algorithm cited in the Cytovene<span class="Sup">®</span>-IV complete product information section on DOSAGE AND ADMINISTRATION: <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The safety and efficacy of VALCYTE have not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<p class="First"><span class="Underline">Experience with VALCYTE Tablets:</span> One adult developed fatal <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> (medullary <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span>) after several days of dosing that was at least 10-fold greater than recommended for the patient's estimated degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. </p>
<p>An <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of VALCYTE could also possibly result in increased renal toxicity <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a>, <a href="#S8.6">Use in Specific Populations (8.6)</a>]</span>.</p>
<p>Because ganciclovir is dialyzable, dialysis may be useful in reducing serum concentrations in patients who have received an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of VALCYTE <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. Adequate hydration should be maintained. The use of hematopoietic growth factors should be considered <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<p class="First"><span class="Underline">Experience with Intravenous Ganciclovir:</span> Reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> with intravenous ganciclovir have been received from clinical trials and during postmarketing experience. The majority of patients experienced one or more of the following adverse events: </p>
<p><span class="Italics">Hematological toxicity:</span> <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, medullary <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span></p>
<p><span class="Italics">Hepatotoxicity:</span> <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, liver function disorder</p>
<p><span class="Italics">Renal toxicity:</span> worsening of <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> in a patient with pre-existing <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, elevated creatinine</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">Gastrointestinal toxicity</span>:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span>:</span> generalized <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">VALCYTE contains valganciclovir hydrochloride (valganciclovir HCl), a hydrochloride salt of the L-valyl ester of ganciclovir that exists as a mixture of two diastereomers. Ganciclovir is a synthetic guanine derivative active against CMV.</p>
<p>VALCYTE is available as a 450 mg tablet for oral administration. Each tablet contains 496.3 mg of valganciclovir HCl (corresponding to 450 mg of valganciclovir), and the inactive ingredients microcrystalline cellulose, povidone K-30, crospovidone and stearic acid. The film-coat applied to the tablets contains Opadry Pink<span class="Sup">®</span>.</p>
<p>VALCYTE is also available as a powder for oral solution, which when constituted with water as directed contains 50 mg/mL valganciclovir free base. The inactive ingredients of VALCYTE for oral solution are sodium benzoate, fumaric acid, povidone K-30, sodium saccharin, mannitol and tutti-frutti flavoring.</p>
<p>Valganciclovir HCl is a white to off-white crystalline powder with a molecular formula of C<span class="Sub">14</span>H<span class="Sub">22</span>N<span class="Sub">6</span>O<span class="Sub">5</span>∙HCl and a molecular weight of 390.83. The chemical name for valganciclovir HCl is L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester, monohydrochloride. Valganciclovir HCl is a polar hydrophilic compound with a solubility of 70 mg/mL in water at 25°C at a pH of 7.0 and an n-octanol/water partition coefficient of 0.0095 at pH 7.0. The pKa for valganciclovir HCl is 7.6.</p>
<p>The chemical structure of valganciclovir HCl is:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dc548ff9-e8ea-4d6e-b9b4-e31f53ac4078&amp;name=valcyte-02.jpg"></p>
<p>All doses in this insert are specified in terms of valganciclovir.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Valganciclovir is an antiviral drug <span class="Italics">[see <a href="#S12.4">Microbiology (12.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Because the major elimination pathway for ganciclovir is renal, dosage reductions according to creatinine clearance are required for VALCYTE tablets and VALCYTE for oral solution <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Underline">Pharmacokinetics in Adults:</span> The pharmacokinetics of valganciclovir and ganciclovir after administration of valganciclovir tablets have been evaluated in HIV- and CMV-seropositive patients, patients with AIDS and <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>, and in solid organ transplant patients.</p>
<p>The ganciclovir pharmacokinetic parameters following administration of 900 mg VALCYTE tablets and 5 mg per kg intravenous ganciclovir and 1000 mg three times daily oral ganciclovir in HIV-positive/CMV-positive patients are summarized in <span class="Bold"><a href="#table10">Table 10</a></span>.</p>
<a name="table10"></a><table width="100%">
<caption><span>Table 10	Mean Ganciclovir Pharmacokinetic<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a> Measures in Healthy Volunteers and HIV-positive/CMV-positive Adults at Maintenance Dosage</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="left" valign="top" width="35%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="middle">Formulation</th>
<th class="Rrule" align="center" valign="middle">VALCYTE Tablets</th>
<th class="Rrule" align="center" valign="middle">Intravenous Ganciclovir</th>
<th class="Rrule" align="center" valign="middle">Ganciclovir Capsules</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Data were obtained from single and multiple dose studies in healthy volunteers, HIV-positive patients, and HIV-positive/CMV-positive patients with and without <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span>. Patients with <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> tended to have higher ganciclovir plasma concentrations than patients without <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">Dosage</td>
<td class="Rrule" align="center">900 mg once daily with food</td>
<td class="Rrule" align="center">5 mg/kg once daily</td>
<td class="Rrule" align="left">1000 mg three times daily with food</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">AUC<span class="Sub">0-24h</span> (µg<span class="Bold">∙</span>h/mL)</td>
<td class="Rrule Toprule" align="center">29.1 ± 9.7<br>(3 studies, n=57)</td>
<td class="Rrule Toprule" align="center">26.5 ± 5.9<br>(4 studies, n=68)</td>
<td class="Rrule Toprule" align="left">Range of means 12.3 to 19.2<br>(6 studies, n=94)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">C<span class="Sub">max </span>(µg/mL)</td>
<td class="Rrule Toprule" align="center">5.61 ± 1.52<br>(3 studies, n=58)</td>
<td class="Rrule Toprule" align="center">9.46 ± 2.02<br>(4 studies, n=68)</td>
<td class="Rrule Toprule" align="left">Range of means 0.955 to 1.40<br>(6 studies, n=94)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Absolute oral bioavailability (%)</td>
<td class="Rrule Toprule" align="center">59.4 ± 6.1<br>(2 studies, n=32)</td>
<td class="Rrule Toprule" align="center">Not Applicable</td>
<td class="Rrule Toprule" align="left">Range of means 6.22 ± 1.29 to<br>8.53 ± 1.53 (2 studies, n=32)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Elimination half-life (hr)</td>
<td class="Rrule Toprule" align="center">4.08 ± 0.76<br>(4 studies, n=73)</td>
<td class="Rrule Toprule" align="center">3.81 ± 0.71<br>(4 studies, n=69)</td>
<td class="Rrule Toprule" align="left">Range of means 3.86 to 5.03<br>(4 studies, n=61)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left">Renal clearance (mL/min/kg)</td>
<td class="Rrule Toprule" align="center">3.21 ± 0.75<br>(1 study, n=20)</td>
<td class="Rrule Toprule" align="center">2.99 ± 0.67<br>(1 study, n=16)</td>
<td class="Rrule Toprule" align="left">Range of means 2.67 to 3.98<br>(3 studies, n=30)</td>
</tr>
</tbody>
</table>
<p>The area under the plasma concentration-time curve (AUC) of ganciclovir administered as VALCYTE tablets (900 mg once daily) is comparable to the AUC of ganciclovir after administration of intravenous ganciclovir (5 mg per kg once daily). The C<span class="Sub">max</span> of ganciclovir following VALCYTE administration is 40% lower than the C<span class="Sub">max</span> following intravenous ganciclovir administration. During maintenance dosing, ganciclovir AUC<span class="Sub">0-24h</span> and C<span class="Sub">max</span> following oral ganciclovir administration (1000 mg three times daily) are lower relative to VALCYTE and intravenous ganciclovir. The ganciclovir C<span class="Sub">min</span> following intravenous ganciclovir and VALCYTE administration are less than the ganciclovir C<span class="Sub">min</span> following oral ganciclovir administration. The clinical significance of the differences in ganciclovir pharmacokinetics after administration of VALCYTE tablets, ganciclovir capsules, and intravenous ganciclovir is unknown.</p>
<a name="figure1"></a><table class="Noautorules" width="100%">
<col align="left" valign="top" width="100%">
<tfoot><tr><td colspan="1" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Plasma concentration-time profiles for ganciclovir (GCV) from valganciclovir (VGCV) and intravenous ganciclovir were obtained from a multiple dose study (n=21 and n=18, respectively) in HIV-positive/CMV-positive patients with <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>. The plasma concentration-time profile for oral ganciclovir was obtained from a multiple dose study (n=24) in HIV-positive/CMV-positive patients without <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>. </dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr><td align="left"><span class="Bold">Figure 1	Ganciclovir Plasma Concentration Time Profiles in HIV-positive/CMV-positive Patients<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></span></td></tr>
<tr><td align="left"><p class="First"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dc548ff9-e8ea-4d6e-b9b4-e31f53ac4078&amp;name=valcyte-03.jpg"></p></td></tr>
</tbody>
</table>
<p>In solid organ transplant recipients, the mean systemic exposure to ganciclovir was 1.7× higher following administration of 900 mg VALCYTE tablets once daily versus 1000 mg ganciclovir capsules three times daily, when both drugs were administered according to their renal function dosing algorithms. The systemic ganciclovir exposures attained were comparable across kidney, heart and liver transplant recipients based on a population pharmacokinetic evaluation (see <span class="Bold"><a href="#table11">Table 11</a></span>).</p>
<a name="table11"></a><table width="75%">
<caption><span>Table 11	Mean Ganciclovir Pharmacokinetic Measures by Organ Transplant Type </span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Parameter</th>
<th class="Rrule" align="center">Ganciclovir Capsules</th>
<th class="Rrule" align="center">VALCYTE Tablets</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Includes kidney-pancreas</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" valign="middle">Dosage</td>
<td class="Rrule" align="center">1000 mg three times daily with food<br>Mean ± SD</td>
<td class="Rrule" align="center">900 mg once daily with food<br>Mean ± SD</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">Heart Transplant Recipients</span></td>
<td class="Rrule Toprule" align="center">N=13</td>
<td class="Rrule Toprule" align="center">N=17</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">AUC<span class="Sub">0-24h</span> (µg<span class="Bold">∙</span>h/mL)</td>
<td class="Rrule" align="center">26.6 ± 11.6</td>
<td class="Rrule" align="center">40.2 ± 11.8</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">C<span class="Sub">max</span> (µg/mL)</td>
<td class="Rrule" align="center">1.4 ± 0.5</td>
<td class="Rrule" align="center">4.9 ± 1.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Elimination half-life (hr)</td>
<td class="Rrule" align="center">8.47 ± 2.84</td>
<td class="Rrule" align="center">6.58 ± 1.50</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Liver Transplant Recipients</span></td>
<td class="Rrule" align="center">N=33</td>
<td class="Rrule" align="center">N=75</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">AUC<span class="Sub">0-24h</span> (µg<span class="Bold">∙</span>h/mL)</td>
<td class="Rrule" align="center">24.9 ± 10.2</td>
<td class="Rrule" align="center">46.0 ± 16.1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">C<span class="Sub">max</span> (µg/mL)</td>
<td class="Rrule" align="center">1.3 ± 0.4</td>
<td class="Rrule" align="center">5.4 ± 1.5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Elimination half-life (hr)</td>
<td class="Rrule" align="center">7.68 ± 2.74</td>
<td class="Rrule" align="center">6.18 ± 1.42</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">Kidney Transplant Recipients<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a></span></td>
<td class="Rrule Toprule" align="center">N=36</td>
<td class="Rrule Toprule" align="center">N=68</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">AUC<span class="Sub">0-24h</span> (µg<span class="Bold">∙</span>h/mL)</td>
<td class="Rrule" align="center">31.3 ± 10.3</td>
<td class="Rrule" align="center">48.2 ± 14.6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">C<span class="Sub">max</span> (µg/mL)</td>
<td class="Rrule" align="center">1.5 ± 0.5</td>
<td class="Rrule" align="center">5.3 ± 1.5</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Elimination half-life (hr)</td>
<td class="Rrule" align="center">9.44 ± 4.37</td>
<td class="Rrule" align="center">6.77 ± 1.25</td>
</tr>
</tbody>
</table>
<p>The pharmacokinetic parameters of ganciclovir following 200 days of VALCYTE administration in high-risk kidney transplant patients were similar to those previously reported in solid organ transplant patients who received VALCYTE for 100 days.</p>
<p>In a pharmacokinetic study in liver transplant patients, the ganciclovir AUC<span class="Sub">0-24h</span> achieved with 900 mg valganciclovir was 41.7 ± 9.9 mcg<span class="Bold">∙</span>h/mL (n=28) and the AUC<span class="Sub">0-24h</span> achieved with the approved dosage of 5 mg per kg intravenous ganciclovir was 48.2 ± 17.3 mcg<span class="Bold">∙</span>h/mL (n=27). </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1.1"></a><p></p>
<p class="First"><span class="Italics">Absorption:</span> Valganciclovir, a prodrug of ganciclovir, is well absorbed from the gastrointestinal tract and rapidly metabolized in the intestinal wall and liver to ganciclovir. The absolute bioavailability of ganciclovir from VALCYTE tablets following administration with food was approximately 60% (3 studies, n=18; n=16; n=28). Ganciclovir median T<span class="Sub">max</span> following administration of 450 mg to 2625 mg VALCYTE tablets ranged from 1 to 3 hours. Dose proportionality with respect to ganciclovir AUC following administration of VALCYTE tablets was demonstrated only under fed conditions. Systemic exposure to the prodrug, valganciclovir, is transient and low, and the AUC<span class="Sub">24</span> and C<span class="Sub">max</span> values are approximately 1% and 3% of those of ganciclovir, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1.2"></a><p></p>
<p class="First"><span class="Italics">Food Effects:</span> When VALCYTE tablets were administered with a high fat meal containing approximately 600 total calories (31.1 g fat, 51.6 g carbohydrates and 22.2 g protein) at a dose of 875 mg once daily to 16 HIV-positive subjects, the steady-state ganciclovir AUC increased by 30% (95% CI 12% to 51%), and the C<span class="Sub">max</span> increased by 14% (95% CI -5% to 36%), without any prolongation in time to peak plasma concentrations (T<span class="Sub">max</span>). VALCYTE should be administered with food <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1.3"></a><p></p>
<p class="First"><span class="Italics">Distribution:</span> Due to the rapid conversion of valganciclovir to ganciclovir, plasma protein binding of valganciclovir was not determined. Plasma protein binding of ganciclovir is 1% to 2% over concentrations of 0.5 and 51 mcg/mL. When ganciclovir was administered intravenously, the steady-state volume of distribution of ganciclovir was 0.703 ± 0.134 L/kg (n=69). </p>
<p>After administration of VALCYTE tablets, no correlation was observed between ganciclovir AUC and reciprocal weight; oral dosing of VALCYTE tablets according to weight is not required. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1.4"></a><p></p>
<p class="First"><span class="Italics">Metabolism</span>: Valganciclovir is rapidly hydrolyzed to ganciclovir; no other metabolites have been detected. No metabolite of orally administered radiolabeled ganciclovir (1000 mg single dose) accounted for more than 1% to 2% of the radioactivity recovered in the feces or urine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1.5"></a><p></p>
<p class="First"><span class="Italics">Elimination</span>: The major route of elimination of valganciclovir is by renal excretion as ganciclovir through glomerular filtration and active tubular secretion. Systemic clearance of intravenously administered ganciclovir was 3.07 ± 0.64 mL/min/kg (n=68) while renal clearance was 2.99 ± 0.67 mL/min/kg (n=16).</p>
<p>The terminal half-life (t<span class="Sub">½</span>) of ganciclovir following oral administration of VALCYTE tablets to either healthy or HIV-positive/CMV-positive subjects was 4.08 ± 0.76 hours (n=73), and that following administration of intravenous ganciclovir was 3.81 ± 0.71 hours (n=69). In heart, kidney, kidney-pancreas, and liver transplant patients, the terminal elimination half-life of ganciclovir following oral administration of VALCYTE was 6.48 ± 1.38 hours, and following oral administration of ganciclovir capsules was 8.56 ± 3.62 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Underline">Specific Populations:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> The pharmacokinetics of ganciclovir from a single oral dose of 900 mg VALCYTE tablets were evaluated in 24 otherwise healthy individuals with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<a name="table12"></a><table width="100%">
<caption><span>Table 12	Pharmacokinetics of Ganciclovir from a Single Oral Dose of 900 mg VALCYTE Tablets</span></caption>
<col align="center" valign="bottom" width="26%">
<col align="center" valign="bottom" width="8%">
<col align="center" valign="bottom" width="22%">
<col align="center" valign="bottom" width="22%">
<col align="center" valign="bottom" width="22%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Estimated Creatinine Clearance<br>(mL/min)</th>
<th class="Lrule" align="center">N</th>
<th class="Lrule" align="center">Apparent Clearance<br>(mL/min)<br>Mean ± SD</th>
<th class="Lrule" align="center">AUC<span class="Sub">last</span><br>(µg∙h/mL)<br>Mean ± SD</th>
<th class="Lrule Rrule" align="center">Half-life<br>(hours)<br>Mean ± SD</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="center">51-70</td>
<td class="Lrule" align="center">6</td>
<td class="Lrule" align="center">249 ± 99</td>
<td class="Lrule" align="center">49.5 ± 22.4</td>
<td class="Lrule Rrule" align="center">4.85 ± 1.4</td>
</tr>
<tr>
<td class="Lrule" align="center">21-50</td>
<td class="Lrule" align="center">6</td>
<td class="Lrule" align="center">136 ± 64</td>
<td class="Lrule" align="center">91.9 ± 43.9</td>
<td class="Lrule Rrule" align="center">10.2 ± 4.4</td>
</tr>
<tr>
<td class="Lrule" align="center">11-20</td>
<td class="Lrule" align="center">6</td>
<td class="Lrule" align="center">45 ± 11</td>
<td class="Lrule" align="center">223 ± 46</td>
<td class="Lrule Rrule" align="center">21.8 ± 5.2</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">≤10</td>
<td class="Lrule" align="center">6</td>
<td class="Lrule" align="center">12.8 ± 8</td>
<td class="Lrule" align="center">366 ± 66</td>
<td class="Lrule Rrule" align="center">67.5 ± 34</td>
</tr>
</tbody>
</table>
<p>Decreased renal function results in decreased clearance of ganciclovir from valganciclovir, and a corresponding increase in terminal half-life. Therefore, dosage adjustment is required for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. </p>
<p>Hemodialysis reduces plasma concentrations of ganciclovir by about 50% following VALCYTE administration. Adult patients receiving hemodialysis (CrCl less than 10 mL/min) cannot use VALCYTE tablets because the daily dose of VALCYTE tablets required for these patients is less than 450 mg <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a> and <a href="#S8.6">Use in Specific Populations (8.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2.2"></a><p></p>
<p class="First"><span class="Italics">Pharmacokinetics in Pediatric Patients:</span> The pharmacokinetics of ganciclovir were evaluated following the administration of valganciclovir in 63 pediatric solid organ transplant patients aged 4 months to 16 years, and in 16  pediatric heart transplant patients less than 4 months of age. In these studies, patients received oral doses of valganciclovir (either VALCYTE for oral solution or tablets) to produce exposure equivalent to an adult 900 mg dose <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>, <a href="#S6.1">Adverse Reactions (6.1)</a>, <a href="#S8.4">Use in Specific Populations (8.4)</a>, <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>
<p>The pharmacokinetics of ganciclovir were similar across organ types and age ranges.  Based on a population pharmacokinetic evaluation, clearance is influenced by both body weight and renal function, while the central and peripheral volumes of distribution were influenced by weight <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a>].</span> The mean total clearance was 5.3 L/hr (88.3 mL/min) for a patient with creatinine clearance of 70.4 mL/min. The mean ganciclovir C<span class="Sub">max</span>, AUC and half-life by age and organ type in studies using the pediatric valganciclovir dosing algorithm are listed in <span class="Bold"><a href="#table13">Table 13</a></span>.  Relative to adult transplant patients (<span class="Bold"><a href="#table11">Table 11</a></span>), AUC values in pediatric patients were somewhat increased, but were within the range considered safe and effective in adults. </p>
<a name="table13"></a><table width="90%">
<caption><span>Table 13	Ganciclovir Pharmacokinetics by Age in Pediatric Solid Organ Transplant Patients<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<thead>
<tr class="First">
<th class="Lrule" align="left" valign="bottom">Organ</th>
<th align="center" valign="bottom">PK Parameter mean (SD)</th>
<th class="Rrule" align="center" colspan="4" valign="middle">Age Group</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th align="left"></th>
<th align="center">&lt; 4 months</th>
<th align="center">4 months to ≤ 2 years</th>
<th align="center">&gt; 2 to &lt; 12 years</th>
<th class="Rrule" align="center">≥ 12 years</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="6">N= number of patients</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Pharmacokinetic parameters were estimated by using population pharmacokinetic modeling.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd>14 heart transplant patients 26 to 124 days of age were included in the population pharmacokinetic model development.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">‡</a></dt>
<dd>19 observations,  some patients contributed more than one value.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">§</a></dt>
<dd>There was one subject in this age group who received both a kidney and liver transplant. The pharmacokinetic profile for this subject has not been included in this table as it is not possible to determine whether the effects observed are from the kidney/liver transplant or neither.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">¶</a></dt>
<dd>The pharmacokinetic profiles for two subjects in this age group who received kidney transplants have not been included in this table as the data were determined to be non-evaluable.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left"></td>
<td align="left">N</td>
<td align="center">14<a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a>
</td>
<td align="center">6</td>
<td align="center">2</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Heart</span></td>
<td align="left">AUC<span class="Sub">0-24h </span>(µg∙h/mL)</td>
<td align="center">66.3 (20.5)<a name="footnote-reference-10" href="#footnote-10" class="Sup">‡</a>
</td>
<td align="center">55.4 (22.8)</td>
<td align="center">59.6 (21.0)</td>
<td class="Rrule" align="center">60.6 (25.0)</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">(N=26)</span></td>
<td align="left">C<span class="Sub">max</span> (µg/mL)</td>
<td align="center">10.8 (3.30)</td>
<td align="center">8.2 (2.5)</td>
<td align="center">12.5 (1.2)</td>
<td class="Rrule" align="center">9.5 (3.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"></td>
<td align="left">t<span class="Sub">1/2</span> (h)</td>
<td align="center">3.5 (0.87)</td>
<td align="center">3.8 (1.7)</td>
<td align="center">2.8 (0.9)</td>
<td class="Rrule" align="center">4.9 (0.8)</td>
</tr>
<tr>
<td class="Lrule" align="left"></td>
<td align="left">N</td>
<td align="center">NA</td>
<td align="center">2</td>
<td align="center">10<a name="footnote-reference-11" href="#footnote-11" class="Sup">§</a><span class="Sup">,</span><a name="footnote-reference-12" href="#footnote-12" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">19</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Kidney</span></td>
<td align="left">AUC<span class="Sub">0-24h </span>(µg∙h/mL)</td>
<td align="center"></td>
<td align="center">67.6 (13.0)</td>
<td align="center">55.9 (12.1)</td>
<td class="Rrule" align="center">47.8 (12.4)</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">(N=31)</span></td>
<td align="left">C<span class="Sub">max</span> (µg/mL)</td>
<td align="center"></td>
<td align="center">10.4 (0.4)</td>
<td align="center">8.7 (2.1)</td>
<td class="Rrule" align="center">7.7 (2.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"></td>
<td align="left">t<span class="Sub">1/2</span> (h)</td>
<td align="center"></td>
<td align="center">4.5 (1.5)</td>
<td align="center">4.8 (1.0)</td>
<td class="Rrule" align="center">6.0 (1.3)</td>
</tr>
<tr>
<td class="Lrule" align="left"></td>
<td align="left">N</td>
<td align="center">NA</td>
<td align="center">9</td>
<td align="center">6</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Liver</span></td>
<td align="left">AUC<span class="Sub">0-24h </span>(µg∙h/mL)</td>
<td align="center"></td>
<td align="center">69.9 (37.0)</td>
<td align="center">59.4 (8.1)</td>
<td class="Rrule" align="center">35.4 (2.8)</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">(N=17)</span></td>
<td align="left">C<span class="Sub">max</span> (µg/mL)</td>
<td align="center"></td>
<td align="center">11.9 (3.7)</td>
<td align="center">9.5 (2.3)</td>
<td class="Rrule" align="center">5.5 (1.1)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"></td>
<td align="left">t<span class="Sub">1/2</span> (h)</td>
<td align="center"></td>
<td align="center">2.8 (1.5)</td>
<td align="center">3.8 (0.7)</td>
<td class="Rrule" align="center">4.4 (0.2)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2.3"></a><p></p>
<p class="First"><span class="Italics">Pharmacokinetics in Geriatric Patients:</span> The pharmacokinetic characteristics of VALCYTE in elderly patients have not been established. Because elderly individuals frequently have a reduced glomerular filtration rate, renal function should be assessed before and during administration of VALCYTE <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a>, <a href="#S8.5">Use in Specific Populations (8.5)</a>]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Underline">Drug Interactions:</span> In vivo drug-drug interaction studies were not conducted with valganciclovir. However, because valganciclovir is rapidly and extensively converted to ganciclovir, interactions associated with ganciclovir will be expected for VALCYTE <span class="Italics">[see <a href="#S7">Drug Interactions (7)</a>].</span></p>
<p>Drug-drug interaction studies were conducted in patients with normal renal function. Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> may have increased concentrations of ganciclovir and the coadministered drug following concomitant administration of VALCYTE and drugs excreted by the same pathway as ganciclovir. Therefore, these patients should be closely monitored for toxicity of ganciclovir and the coadministered drug.</p>
<p><span class="Bold"><a href="#table14">Table 14</a></span> and <span class="Bold"><a href="#table15">Table 15</a></span> provide a listing of established drug interaction studies with ganciclovir. <span class="Bold"><a href="#table14">Table 14</a></span> provides the effects of coadministered drug on ganciclovir plasma pharmacokinetic parameters, whereas <span class="Bold"><a href="#table15">Table 15</a></span> provides the effects of ganciclovir on plasma pharmacokinetic parameters of coadministered drug.</p>
<a name="table14"></a><table width="75%">
<caption><span>Table 14	Results of Drug Interaction Studies with Ganciclovir: Effects of Coadministered Drug on Ganciclovir Pharmacokinetic Parameters</span></caption>
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="10%">
<col align="left" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="middle">Coadministered Drug</th>
<th class="Rrule" align="center" valign="middle">Ganciclovir Dosage</th>
<th class="Rrule" align="center" valign="middle">N</th>
<th class="Rrule" align="center" valign="middle">Ganciclovir Pharmacokinetic (PK) Parameter</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Zidovudine 100 mg every 4 hours</td>
<td class="Rrule" align="left">1000 mg every 8 hours</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="left">AUC ↓ 17 ± 25%<br>(range: -52% to 23%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Probenecid 500 mg every 6 hours</td>
<td class="Botrule Rrule" align="left">1000 mg every 8 hours</td>
<td class="Botrule Rrule" align="center">10</td>
<td class="Botrule Rrule" align="left">AUC ↑ 53 ± 91%<br>(range: -14% to 299%)<br>Ganciclovir renal clearance ↓ 22 ± 20%<br>(range: -54% to -4%)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Mycophenolate Mofetil (MMF) 1.5 g single dose</td>
<td class="Botrule Rrule" align="left">IV ganciclovir 5 mg/kg single dose</td>
<td class="Botrule Rrule" align="center">12</td>
<td class="Botrule Rrule" align="left">No effect on ganciclovir PK parameters observed (patients with normal renal function)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Didanosine 200 mg every 12 hours administered 2 hours before ganciclovir</td>
<td class="Botrule Rrule" align="left">1000 mg every 8 hours</td>
<td class="Botrule Rrule" align="center">12</td>
<td class="Botrule Rrule" align="left">AUC ↓ 21 ± 17%<br>(range: -44% to 5%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left" rowspan="3">Didanosine 200 mg every 12 hours simultaneously administered with ganciclovir</td>
<td class="Rrule" align="left">1000 mg every 8 hours</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="left">No effect on ganciclovir PK parameters observed</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">IV ganciclovir 5 mg/kg twice daily</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="left">No effect on ganciclovir PK parameters observed</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">IV ganciclovir 5 mg/kg once daily</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="left">No effect on ganciclovir PK parameters observed</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Trimethoprim 200 mg once daily</td>
<td class="Rrule" align="left">1000 mg every 8 hours</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="left">Ganciclovir renal clearance ↓ 16.3%<br>Half-life ↑15%</td>
</tr>
</tbody>
</table>
<a name="table15"></a><table width="75%">
<caption><span>Table 15	Results of Drug Interaction Studies with Ganciclovir: Effects of Ganciclovir on Pharmacokinetic Parameters of Coadministered Drug</span></caption>
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="10%">
<col align="left" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="middle">Coadministered Drug</th>
<th class="Rrule" align="center" valign="middle">Ganciclovir Dosage</th>
<th class="Rrule" align="center" valign="middle">N</th>
<th class="Rrule" align="center" valign="middle">Coadministered Drug Pharmacokinetic (PK) Parameter</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Zidovudine 100 mg every 4 hours</td>
<td class="Rrule" align="left">1000 mg every 8 hours</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="left">AUC<span class="Sub">0-4</span> ↑ 19 ± 27%<br>(range: -11% to 74%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Mycophenolate Mofetil (MMF) 1.5 g single dose</td>
<td class="Rrule" align="left">IV ganciclovir 5 mg/kg single dose</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="left">No PK interaction observed (patients with normal renal function)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Didanosine 200 mg every 12 hours when administered 2 hours prior to or concurrent with ganciclovir</td>
<td class="Rrule" align="left">1000 mg every 8 hours</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="left">AUC<span class="Sub">0-12</span> ↑111 ± 114%<br>(range: 10% to 493%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Didanosine 200 mg every 12 hours</td>
<td class="Rrule" align="left">IV ganciclovir 5 mg/kg twice daily</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="left">AUC<span class="Sub">0-12</span> ↑70 ± 40%<br>(range: 3% to 121%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="left">C<span class="Sub">max</span>↑49 ± 48%<br>(range: -28% to 125%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Didanosine 200 mg every 12 hours</td>
<td class="Rrule" align="left">IV ganciclovir 5 mg/kg once daily</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="left">AUC<span class="Sub">0-12</span> ↑50 ± 26%<br>(range: 22% to 110%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="left">C<span class="Sub">max</span> ↑36 ± 36%<br>(range: -27% to 94%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Trimethoprim 200 mg once daily</td>
<td class="Rrule" align="left">1000 mg every 8 hours</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="left">Increase (12%) in C<span class="Sub">min</span>
</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3.1"></a><p></p>
<p class="First"><span class="Italics">Other potential drug interactions</span></p>
<p>Since ganciclovir is excreted through the kidney via glomerular filtration and active secretion <span class="Italics">[see <a href="#S12.3">Pharmacokinetics (12.3)</a>]</span>, coadministration of valganciclovir with antiretroviral drugs that share the tubular secretion pathway, such as nucleos(t)ide reverse transcriptase inhibitors, may change the plasma concentrations of valganciclovir and/or the coadministered drug.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="S12.4"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Mechanism of Action:</span> Valganciclovir is an L-valyl ester (prodrug) of ganciclovir that exists as a mixture of two diastereomers. After oral administration, both diastereomers are rapidly converted to ganciclovir by intestinal and hepatic esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, which inhibits replication of human CMV in cell culture and in vivo. </p>
<p>In CMV-infected cells ganciclovir is initially phosphorylated to ganciclovir monophosphate by the viral protein kinase, pUL97. Further phosphorylation occurs by cellular kinases to produce ganciclovir triphosphate, which is then slowly metabolized intracellularly (half-life 18 hours). As the phosphorylation is largely dependent on the viral kinase, phosphorylation of ganciclovir occurs preferentially in virus-infected cells. The virustatic activity of ganciclovir is due to inhibition of the viral DNA polymerase, pUL54, synthesis by ganciclovir triphosphate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Antiviral Activity:</span> The quantitative relationship between the cell culture susceptibility of human herpes viruses to antivirals and clinical response to antiviral therapy has not been established, and virus sensitivity testing has not been standardized. Sensitivity test results, expressed as the concentration of drug required to inhibit the growth of virus in cell culture by 50% (EC<span class="Sub">50</span>), vary greatly depending upon a number of factors including the assay used. Thus, the reported EC<span class="Sub">50</span> values of ganciclovir that inhibit human CMV replication in cell culture (laboratory and clinical isolates) have ranged from 0.08 to 22.94 µM (0.02 to 5.75 mcg/mL). The distribution and range in susceptibility observed in one assay evaluating 130 clinical isolates was 0 to 1 µM (35%), 1.1 to 2 µM (20%), 2.1 to 3 µM (27%), 3.1 to 4 µM (13%), 4.1 to 5 µM (5%), less than 5 µM (less than 1%). Ganciclovir inhibits mammalian cell proliferation (CC<span class="Sub">50</span>) in cell culture at higher concentrations ranging from 40 to greater than 1,000 µM (10.21 to greater than 250 mcg/mL). Bone marrow-derived colony-forming cells are more sensitive [CC<span class="Sub">50</span> value = 2.7 to 12 µM (0.69 to 3.06 mcg/mL)]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Viral Resistance:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3.1"></a><p></p>
<p class="First">Cell culture: CMV isolates with reduced susceptibility to ganciclovir have been selected in cell culture. Growth of CMV <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> in the presence of ganciclovir resulted in the selection of amino acid substitutions in the viral protein kinase pUL97 (M460I/V, L595S, G598D, and K599T) and the viral DNA polymerase pUL54 (D301N, N410K, F412V, P488R, L516R, C539R, L545S, F595I, V812L, P829S, L862F, D879G, and V946L).  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3.2"></a><p></p>
<p class="First">In vivo: Viruses resistant to ganciclovir can arise after prolonged treatment or prophylaxis with valganciclovir by selection of substitutions in pUL97 and/or pUL54. Limited clinical data are available on the development of clinical resistance to ganciclovir and many pathways to resistance likely exist. In clinical isolates, seven canonical pUL97 substitutions, (M460V/I, H520Q, C592G, A594V, L595S, C603W) are the most frequently reported ganciclovir resistance-associated substitutions. These and other substitutions less frequently reported in the literature, or observed in clinical trials, are listed in <span class="Bold"><a href="#table16">Table 16</a>.</span></p>
<a name="table16"></a><table width="100%">
<caption><span>Table 16	Summary of Resistance-associated Amino Acid Substitutions Observed in the CMV of Patients Failing Ganciclovir Treatment or Prophylaxis</span></caption>
<col align="left" valign="middle" width="10%">
<col align="left" valign="middle" width="90%">
<tfoot><tr class="First Last"><td align="left" colspan="2">Note: Many additional pathways to ganciclovir resistance likely exist</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">pUL97</td>
<td class="Rrule" align="left">L405P, A440V, M460I/V/T, V466G/M, C518Y, H520Q, del 590-593, A591D/V, C592G, A594E/G/T/V/P, L595F/S/T/W, del 595, del 595-603, E596D/G, K599E/M, del 600-601, del 597-600, del 601-603, C603W/R/S/Y, C607F/S/Y, A613V</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">pUL54</td>
<td class="Rrule" align="left">E315D, N408D/K/S, F412C/L/S, D413A/E, L501F/I, T503I, K513E/N/R, I521T, P522A/L/S, L545S/W, Q578H/L, D588E/N, G629S, S695T, I726T/V, E756K, V781I, V787L, L802M, A809V, T813S, T821I, A834P, G841A/S, D879G, A972V, del 981-982, A987G</td>
</tr>
</tbody>
</table>
<p>The presence of known ganciclovir resistance-associated amino acid substitutions was evaluated in a study that extended valganciclovir CMV prophylaxis from 100 days to 200 days post-transplant in adult kidney transplant patients at high risk for CMV disease (D+/R-) <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1)</a>]</span>. Five subjects from the 100 day group and four subjects from the 200 day group meeting the resistance analysis criteria had known ganciclovir resistance-associated amino acid substitutions detected. In six subjects, the following resistance-associated amino acid substitutions were detected within pUL97: 100 day group: A440V, M460V, C592G; 200 day group: M460V, C603W. In three subjects, the following resistance-associated amino acid substitutions were detected within pUL54: 100 day group: E315D, 200 day group: E315D, P522S. Overall, the detection of known ganciclovir resistance-associated amino acid substitutions was observed more frequently in patients during prophylaxis therapy than after the completion of prophylaxis therapy (during therapy: 5/12 [42%] versus after therapy: 4/58 [7%]). The possibility of viral resistance should be considered in patients who show poor clinical response or experience persistent viral excretion during therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Cross-Resistance:</span> Cross-resistance has been reported for amino acid substitutions selected in cell culture by ganciclovir, cidofovir or foscarnet. In general, amino acid substitutions in pUL54 conferring cross-resistance to ganciclovir and cidofovir are located within the exonuclease domains and region V. Whereas, amino acid substitutions conferring cross-resistance to foscarnet are diverse, but concentrate at and between regions II (codon 696-742) and III (codon 805-845). The amino acid substitutions that resulted in reduced susceptibility to ganciclovir and either cidofovir and/or foscarnet are summarized in <a href="#table17">Table 17</a>.</p>
<p>Substitutions at amino acid positions pUL97 340-400 have been found to confer resistance to ganciclovir.  Resistance data based on assays that do not include this region should be interpreted cautiously.</p>
<a name="table17"></a><table width="100%">
<caption><span>Table 17	Summary of pUL54 Amino Acid Substitutions with Cross-Resistance between Ganciclovir, Cidofovir, and/or Foscarnet</span></caption>
<col align="left" valign="middle" width="25%">
<col align="left" valign="middle" width="75%">
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Cross-resistant to cidofovir</span></td>
<td class="Rrule" align="left">D301N, N408D/K, N410K, F412C/L/S/V, D413E, L501I, T503I, K513E/N, L516R, I521T, P522S/A, L545S/W, Q578H, D588N, I726T/V, E756K, V812L, T813S, A834P, G841A, del 981-982, A987G</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Cross-resistant to foscarnet</span></td>
<td class="Rrule" align="left">F412C, Q578H/L, D588N, E756K, V781I, V787L, L802M, A809V, V812L, T813S, T821I, A834P, G841A, del 981-982</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term carcinogenicity studies have not been conducted with VALCYTE. However, upon oral administration, valganciclovir is rapidly and extensively converted to ganciclovir. Therefore, like ganciclovir, valganciclovir is a potential carcinogen. </p>
<p>Ganciclovir was carcinogenic in the mouse at oral doses that produced exposures approximately 0.1× and 1.4×, respectively, the mean drug exposure in humans following the recommended intravenous dose of 5 mg/kg, based on area under the plasma concentration curve (AUC) comparisons. At the higher dose there was a significant increase in the incidence of tumors of the preputial gland in males, forestomach (nonglandular mucosa) in males and females, and reproductive tissues (ovaries, uterus, mammary gland, clitoral gland and vagina) and liver in females. At the lower dose, a slightly increased incidence of tumors was noted in the preputial and harderian glands in males, forestomach in males and females, and liver in females. Ganciclovir should be considered a potential carcinogen in humans. </p>
<p>Valganciclovir increases mutations in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells. In the mouse micronucleus assay, valganciclovir was clastogenic. Valganciclovir was not mutagenic in the Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> assay. Ganciclovir increased mutations in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells and DNA damage in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> in vitro. In the mouse micronucleus assay, ganciclovir was clastogenic. Ganciclovir was not mutagenic in the Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> assay. </p>
<p>Valganciclovir is converted to ganciclovir and therefore is expected to have similar reproductive toxicity effects as ganciclovir <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>. Ganciclovir caused decreased mating behavior, decreased fertility, and an increased incidence of embryolethality in female mice following intravenous doses that produced an exposure approximately 1.7× the mean drug exposure in humans following the dose of 5 mg per kg, based on AUC comparisons. Ganciclovir caused decreased fertility in male mice and hypospermatogenesis in mice and dogs following daily oral or intravenous administration. Systemic drug exposure (AUC) at the lowest dose showing toxicity in each species ranged from 0.03 to 0.1× the AUC of the recommended human intravenous dose. Valganciclovir caused similar effects on spermatogenesis in mice, rats, and dogs. These effects were reversible at lower doses but irreversible at higher doses. It is considered likely that ganciclovir (and valganciclovir) could cause temporary or permanent inhibition of human spermatogenesis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Adult Patients</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Underline">Induction Therapy of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span>:</span> In one randomized open-label controlled study, 160 patients with AIDS and newly diagnosed <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> were randomized to receive treatment with either VALCYTE tablets (900 mg twice daily for 21 days, then 900 mg once daily for 7 days) or with intravenous ganciclovir solution (5 mg per kg twice daily for 21 days, then 5 mg per kg once daily for 7 days). Study participants were: male (91%), White (53%), Hispanic (31%), and Black (11%). The median age was 39 years, the median baseline HIV-1 RNA was 4.9 log<span class="Sub">10</span>, and the median CD4 cell count was 23 cells/mm<span class="Sup">3</span>. A determination of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> progression by the masked review of retinal photographs taken at baseline and Week 4 was the primary outcome measurement of the 3-week induction therapy. <span class="Bold"><a href="#table18">Table 18</a></span> provides the outcomes at 4 weeks.</p>
<a name="table18"></a><table width="75%">
<caption><span>Table 18	Week 4 Masked Review of Retinal Photographs in <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span> Study</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule Rrule" align="center">Intravenous Ganciclovir</th>
<th class="Rrule" align="center">VALCYTE Tablets</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Determination of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> progression at Week 4</td>
<td class="Botrule Lrule Rrule" align="center">N=80</td>
<td class="Botrule Rrule" align="center">N=80</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Progressor</td>
<td class="Lrule Rrule" align="center">7</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Non-progressor</td>
<td class="Lrule Rrule" align="center">63</td>
<td class="Rrule" align="center">64</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule" align="left">Discontinuations due to Adverse Events</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule" align="left">Failed to return</td>
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Last">
<td class="Lrule Toprule" align="left">CMV not confirmed at baseline or no interpretable baseline photos</td>
<td class="Lrule Rrule Toprule" align="center">6</td>
<td class="Rrule Toprule" align="center">5</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Underline">Maintenance Therapy of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span>:</span> No comparative clinical data are available on the efficacy of VALCYTE tablets for the maintenance therapy of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> because all patients in the <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> study received open-label VALCYTE tablets after Week 4. However, the AUC for ganciclovir is similar following administration of 900 mg VALCYTE tablets once daily and 5 mg per kg intravenous ganciclovir once daily. Although the ganciclovir C<span class="Sub">max</span> is lower following VALCYTE tablets administration compared to intravenous ganciclovir, it is higher than the C<span class="Sub">max</span> obtained following oral ganciclovir administration <span class="Italics">[see <span class="Bold"><a href="#figure1">Figure 1</a></span> in Clinical Pharmacology (12.3)]</span>. Therefore, use of VALCYTE tablets as maintenance therapy is supported by a plasma concentration-time profile similar to that of two approved products for maintenance therapy of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.3"></a><p></p>
<p class="First"><span class="Underline">Prevention of CMV Disease in Heart, Kidney, Kidney-Pancreas, or Liver Transplantation:</span> A double blind, double-dummy active comparator study was conducted in 372 heart, liver, kidney, or kidney-pancreas transplant patients at high risk for CMV disease (D+/R-). Patients were randomized (2 VALCYTE: 1 oral ganciclovir) to receive either VALCYTE tablets (900 mg once daily) or oral ganciclovir (1000 mg three times a day) starting within 10 days of transplantation until Day 100 post-transplant. The proportion of patients who developed CMV disease, including CMV syndrome and/or tissue-invasive disease during the first 6 months post-transplant was similar between the VALCYTE tablets arm (12.1%, N=239) and the oral ganciclovir arm (15.2%, N=125). However, in liver transplant patients, the incidence of tissue-invasive CMV disease was significantly higher in the VALCYTE group compared with the ganciclovir group. These results are summarized in <span class="Bold"><a href="#table19">Table 19</a></span>.</p>
<p>Mortality at six months was 3.7% (9/244) in the VALCYTE group and 1.6% (2/126) in the oral ganciclovir group. </p>
<a name="table19"></a><table width="85%">
<caption><span>Table 19	Percentage of Patients with CMV Disease, Tissue-Invasive CMV Disease or CMV syndrome by Organ Type: Endpoint Committee, 6 Month ITT Population</span></caption>
<col align="left" valign="top" width="16%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">CMV Disease<a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a>
</th>
<th class="Rrule" align="center" colspan="2">Tissue-Invasive CMV Disease</th>
<th class="Rrule" align="center" colspan="2">CMV Syndrome<a name="footnote-reference-14" href="#footnote-14" class="Sup">†</a>
</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">														Organ 													</th>
<th class="Rrule" align="center">VGCV<br>(N=239)</th>
<th class="Rrule" align="center">GCV<br>(N=125)</th>
<th class="Rrule" align="center">VGCV<br>(N=239)</th>
<th class="Rrule" align="center">GCV<br>(N=125)</th>
<th class="Rrule" align="center">VGCV<br>(N=239)</th>
<th class="Rrule" align="center">GCV<br>(N=125)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="7">GCV = oral ganciclovir; VGCV = valganciclovir</td></tr>
<tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>Number of patients with CMV disease = Number of patients with tissue-invasive CMV disease or CMV syndrome</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">†</a></dt>
<dd>CMV syndrome was defined as evidence of <span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span> accompanied with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> greater than or equal to 38°C on two or more occasions separated by at least 24 hours within a 7-day period and one or more of the following: <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, atypical <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and elevation of hepatic transaminases</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Liver<br>(n=177)</td>
<td class="Rrule" align="center">19%<br>(22 / 118)</td>
<td class="Rrule" align="center">12%<br>(7 / 59)</td>
<td class="Rrule" align="center">14%<br>(16 / 118)</td>
<td class="Rrule" align="center">3%<br>(2 / 59)</td>
<td class="Rrule" align="center">5%<br>(6 / 118)</td>
<td class="Rrule" align="center">9%<br>(5 / 59)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Kidney<br>(n=120)</td>
<td class="Rrule" align="center">6%<br>(5 / 81)</td>
<td class="Rrule" align="center">23%<br>(9 / 39)</td>
<td class="Rrule" align="center">1%<br>(1 / 81)</td>
<td class="Rrule" align="center">5%<br>(2 / 39)</td>
<td class="Rrule" align="center">5%<br>(4 / 81)</td>
<td class="Rrule" align="center">18%<br>(7 / 39)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Heart<br>(n=56)</td>
<td class="Rrule" align="center">6%<br>(2 / 35)</td>
<td class="Rrule" align="center">10%<br>(2 / 21)</td>
<td class="Rrule" align="center">0%<br>(0 / 35)</td>
<td class="Rrule" align="center">5%<br>(1 / 21)</td>
<td class="Rrule" align="center">6%<br>(2 / 35)</td>
<td class="Rrule" align="center">5%<br>(1 / 21)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Kidney / Pancreas<br>(n=11)</td>
<td class="Rrule" align="center">0%<br>(0 / 5)</td>
<td class="Rrule" align="center">17%<br>(1 / 6)</td>
<td class="Rrule" align="center">0%<br>(0 / 5)</td>
<td class="Rrule" align="center">17%<br>(1 / 6)</td>
<td class="Rrule" align="center">0%<br>(0 / 5)</td>
<td class="Rrule" align="center">0%<br>(0 / 6)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.4"></a><p></p>
<p class="First"><span class="Underline">Prevention of CMV Disease in Kidney Transplantation:</span> A double-blind, placebo-controlled study was conducted in 326 kidney transplant patients at high risk for CMV disease (D+/R-) to assess the efficacy and safety of extending VALCYTE CMV prophylaxis from 100 to 200 days post-transplant. Patients were randomized (1:1) to receive VALCYTE tablets (900 mg once daily) within 10 days of transplantation either until Day 200 post-transplant or until Day 100 post-transplant followed by 100 days of placebo. Extending CMV prophylaxis with VALCYTE until Day 200 post-transplant demonstrated superiority in preventing CMV disease within the first 12 months post-transplant in high risk kidney transplant patients compared to the 100 day dosing regimen (primary endpoint). These results are summarized in <span class="Bold"><a href="#table20">Table 20</a>.</span></p>
<a name="table20"></a><table width="85%">
<caption><span>Table 20	Percentage of Kidney Transplant Patients with CMV Disease, Tissue-Invasive CMV Disease or CMV Syndrome, 12 Month ITT Population</span></caption>
<col align="left" valign="top" width="16%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">CMV Disease<a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a>
</th>
<th class="Rrule" align="center" colspan="2">Tissue-Invasive CMV Disease</th>
<th class="Rrule" align="center" colspan="2">CMV Syndrome<a name="footnote-reference-16" href="#footnote-16" class="Sup">†</a>
</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">100 Days<br>VGCV<br>(N=163)</th>
<th class="Rrule" align="center">200 Days<br>VGCV<br>(N=155)</th>
<th class="Rrule" align="center">100 Days<br>VGCV<br>(N=163)</th>
<th class="Rrule" align="center">200 Days<br>VGCV<br>(N=155)</th>
<th class="Rrule" align="center">100 Days<br>VGCV<br>(N=163)</th>
<th class="Rrule" align="center">200 Days<br>VGCV<br>(N=155)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="7">VGCV = valganciclovir.</td></tr>
<tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>Number of patients with CMV disease = Number of patients with tissue-invasive CMV disease or CMV syndrome</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">†</a></dt>
<dd>CMV syndrome was defined as evidence of <span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span> accompanied with at least one of the following: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (greater than or equal to 38°C), severe <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, atypical <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and elevation of hepatic transaminases </dd>
<dt><a name="footnote-17" href="#footnote-reference-17">‡</a></dt>
<dd>Two patients in the 100 day group had both tissue-invasive CMV disease and CMV syndrome; however, these patients are counted as having only tissue-invasive CMV disease.</dd>
</dl></td></tr>
</tfoot>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="left">Cases</td>
<td class="Rrule" align="center">36.8%<br>(60/163)</td>
<td class="Rrule" align="center">16.8%<br>(26/155)</td>
<td class="Rrule" align="center">1.8%<br>(3/163)<a name="footnote-reference-17" href="#footnote-17" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.6%<br>(1/155)</td>
<td class="Rrule" align="center">35. 0%<br>(57/163)</td>
<td class="Rrule" align="center">16.1%<br>(25/155)</td>
</tr></tbody>
</table>
<p>	The percentage of kidney transplant patients with CMV disease at 24 months post-transplant was 38.7% (63/163) for the 100 day dosing regimen and 21.3% (33/155) for the 200 day dosing regimen.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2	Pediatric Patients</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2.1"></a><p></p>
<p class="First"><span class="Underline">Prevention of CMV in Pediatric Heart, Kidney, or Liver Transplantation:</span> Sixty-three children, 4 months to 16 years of age, who had a solid organ transplant (kidney 33, liver 17, heart 12, and kidney/liver 1) and were at risk for developing CMV disease, were enrolled in an open-label, safety, and pharmacokinetic study of oral VALCYTE (VALCYTE for oral solution or tablets). Patients received VALCYTE once daily within 10 days after transplant until a maximum of 100 days post-transplant. The daily doses of VALCYTE were calculated at each study visit based on body surface area and a modified creatinine clearance <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>]</span>. </p>
<p>The pharmacokinetics of ganciclovir were similar across organ transplant types and age ranges. The mean daily ganciclovir exposures in pediatric patients were somewhat increased relative  to those observed in adult solid organ transplant patients receiving VALCYTE 900 mg once daily, but were within the range considered safe and effective in adults <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. No case of CMV syndrome or tissue-invasive CMV disease was reported within the first six months post-transplantation. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2.2"></a><p></p>
<p class="First"><span class="Underline">Prevention of CMV in Pediatric Kidney Transplantation:</span> Fifty-seven children, 1 to 16 years of age, who had a renal transplant and were at risk for developing CMV disease, were enrolled in an open-label tolerability study of oral VALCYTE (VALCYTE for oral solution or tablets). Patients received VALCYTE once daily within 10 days after transplant until a maximum of 200 days post-transplant. The daily doses of VALCYTE were calculated at each study visit based on body surface area and a modified creatinine clearance <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>].</span> No case of CMV syndrome or tissue-invasive CMV disease was reported within the first 12 months post-transplantation.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<p class="First">1. Brion, L.P., Fleischman, A.R., McCarton, C., Schwartz, G.J.  A simple estimate of glomerular filtration rate in low birth weight infants during the first year of life: noninvasive assessment of body composition and growth. J of Ped 1986: 109(4): 698-707. </p>
<p>2. NIOSH [2014]. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings. By Connor T.H., MacKenzie B.A., DeBord D.G., Trout D.B., O'Callaghan J.P., Cincinnati, O.H.: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2014-138 (Supersedes 2012-150).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<p class="First"><span class="Underline">VALCYTE tablets:</span> Supplied as 450 mg, pink, convex oval tablets with "VGC" on one side and "450" on the other side. Each tablet contains valganciclovir HCl equivalent to 450 mg valganciclovir. VALCYTE is supplied in bottles of 60 tablets (NDC 0004-0038-22).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.1.1"></a><p></p>
<p class="First">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP controlled room temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2"></a><p></p>
<p class="First"><span class="Underline">VALCYTE for oral solution:</span> Supplied as a white to slightly yellow powder blend for constitution, forming a colorless to brownish yellow tutti-frutti flavored solution. Available in glass bottles containing approximately 100 mL of solution after constitution. Each bottle can deliver up to a total of 88 mL of solution. Each bottle is supplied with a bottle adapter and 2 oral dispensers (NDC 0004-0039-09).</p>
<p>Prior to dispensing to the patient, VALCYTE for oral solution must be prepared by the pharmacist <span class="Italics">[see <a href="#S2.4">Dosage and Administration (2.4)</a>].</span></p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.2.1"></a><p></p>
<p class="First">Store dry powder at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP controlled room temperature].</p>
<p>Store constituted solution under refrigeration at 2°C to 8°C (36°F to 46°F) for no longer than 49 days. Do not freeze.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<p class="First"><span class="Bold">Serious Adverse Reactions</span></p>
<p>Inform patients that VALCYTE may cause <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and elevated creatinine levels and that dose modification or discontinuation of dosing may be required. Complete blood counts, platelet counts, and creatinine levels should be performed frequently during treatment <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.2"></a><p></p>
<p class="First"><span class="Bold">Pregnancy and Contraception</span></p>
<p>Inform females of reproductive potential that VALCYTE causes <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in animals. Advise them to use effective contraception during and for at least 30 days following treatment with VALCYTE. Similarly, advise males to practice barrier contraception during and for at least 90 days following treatment with VALCYTE <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1</a>, <a href="#S8.3">8.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.3"></a><p></p>
<p class="First"><span class="Bold">Carcinogenicity</span></p>
<p>Advise patients that VALCYTE is considered a potential carcinogen <span class="Italics">[see <a href="#S13.1">Nonclinical Toxicity (13.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.4"></a><p></p>
<p class="First"><span class="Bold">Lactation</span></p>
<p>Advise mothers not to breast-feed if they are receiving VALCYTE because of the potential for hematologic toxicity and cancer in nursing infants, and because HIV can be passed to the baby in breast milk <span class="Italics">[see <a href="#S8.2">Use in Specific Populations (8.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.5"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span></span></p>
<p>Advise patients that VALCYTE may cause temporary or permanent female and male <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>, <a href="#S8.3">Use in Specific Populations (8.3)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.6"></a><p></p>
<p class="First"><span class="Bold">Impairment of Cognitive Ability </span></p>
<p>Inform patients that tasks requiring alertness may be affected including the patient's ability to drive and operate machinery as <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, sedation, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> and/or <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> have been reported with the use of VALCYTE <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.7"></a><p></p>
<p class="First"><span class="Bold">Use in Patients with <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span></span></p>
<p>Inform patients that VALCYTE is not a cure for <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>, and they may continue to experience progression of <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> during or following treatment. Advise patients to have ophthalmologic follow-up examinations at a minimum of every 4 to 6 weeks while being treated with VALCYTE. Some patients will require more frequent follow-up.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.8"></a><p></p>
<p class="First"><span class="Bold">Administration</span></p>
<p>Inform adult patients that they should use VALCYTE tablets, not VALCYTE for oral solution <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1)</a>]</span>.</p>
<p>Inform patients to take VALCYTE with food to maximize bioavailability.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-17"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><span class="Bold">VALCYTE (Val-site) <br>(valganciclovir hydrochloride)<br>tablets</span></p>
<p><span class="Bold">VALCYTE (Val-site)<br>(valganciclovir hydrochloride)<br>oral solution</span></p>
<p><a name="important"></a><span class="Bold">What is the most important information I should know about VALCYTE?</span></p>
<ul>
<li>
<span class="Bold">VALCYTE can affect your blood cells and bone marrow causing serious and life-threatening problems.</span> VALCYTE can lower the amount of your white blood cells, red blood cells, and platelets. Your healthcare provider may do regular blood tests to check your blood cell counts while you are taking VALCYTE. Based on these tests, your healthcare provider may change your dose or tell you to stop taking VALCYTE.</li>
<li>
<span class="Bold">VALCYTE may cause cancer.</span> VALCYTE causes cancer in animals. It is not known if VALCYTE causes cancer in people.</li>
<li>
<span class="Bold">VALCYTE may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>.</span> VALCYTE causes <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in animals. It is not known if VALCYTE causes <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in people. <span class="Bold">If you are pregnant, talk to your healthcare provider before taking VALCYTE.</span><ul class="Disc">
<li><span class="Bold">If you are a female who can become pregnant, you should have a pregnancy test done before starting VALCYTE.</span></li>
<li><span class="Bold">If you are a female who can become pregnant, you should use effective birth control during treatment with VALCYTE and for at least 30 days after treatment.</span></li>
<li><span class="Bold">Tell your healthcare provider right away if you become pregnant while taking VALCYTE. </span></li>
<li>
<span class="Bold">Men should use a condom during treatment with VALCYTE, and for at least 90 days after treatment, if their female sexual partner can become pregnant.</span> Talk to your healthcare provider if you have questions about birth control.</li>
</ul>
</li>
<li><span class="Bold">VALCYTE may lower the amount of sperm in a man's body and cause fertility problems. VALCYTE may also cause fertility problems in women.  Talk to your healthcare provider if this is a concern for you. </span></li>
<li>
<span class="Bold">VALCYTE can affect your kidneys, including serious problems such as <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>.</span> Your healthcare provider may do regular blood tests to check your kidney function while you are taking VALCYTE. Your healthcare provider may adjust your dose based on these tests. </li>
<li>
<span class="Bold">VALCYTE changes into the medicine ganciclovir once it is in your body.</span> Ganciclovir is also the active ingredient in Cytovene<span class="Sup">®</span>-IV. Do not take Cytovene-IV if you are taking VALCYTE. <span class="Bold">You could <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and become very sick if VALCYTE is taken with Cytovene-IV.</span> Talk to your healthcare provider or pharmacist if you have questions about your medicine.</li>
</ul>
<p><span class="Bold">What is VALCYTE?</span></p>
<p>VALCYTE is a prescription antiviral medicine.</p>
<p><span class="Bold">In adults, VALCYTE tablets are used:</span></p>
<ul>
<li>to treat cytomegalovirus (CMV) <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> in people who have <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span> (AIDS). When CMV virus infects the eyes, it is called <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>. If <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> is left untreated, it can cause <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>.</li>
<li>to prevent cytomegalovirus (CMV) disease in people who have received a <span class="Bold">heart, kidney, or kidney-pancreas</span> transplant and who have a high risk for getting CMV disease.</li>
</ul>
<p><span class="Bold">In children, VALCYTE tablets or oral solution are used:</span></p>
<ul>
<li>to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years of age who have received a <span class="Bold">kidney</span> transplant and have a high risk for getting CMV disease.</li>
<li>to prevent cytomegalovirus (CMV) disease in children 1 month to 16 years of age who have received a <span class="Bold">heart</span> transplant and have a high risk for getting CMV disease.</li>
</ul>
<p><span class="Bold">VALCYTE does not cure <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>.</span> You may still get <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> or worsening of <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> during or after treatment with VALCYTE. It is important to stay under a healthcare provider's care and have your eyes checked every 4 to 6 weeks during treatment with VALCYTE.</p>
<p><span class="Bold">Who should not take VALCYTE? </span></p>
<p><span class="Bold">Do not take VALCYTE if you are allergic to any of its ingredients or if you have ever had a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to ganciclovir capsules or Cytovene-IV.</span> Symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to VALCYTE may include: sudden trouble breathing, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> all over your body, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> around your mouth, or feeling anxious. </p>
<p>See the <span class="Underline"><a href="#end">end of this leaflet</a></span> for a list of the ingredients in VALCYTE.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking VALCYTE?</span></p>
<p><span class="Bold">Before taking VALCYTE, tell your healthcare provider if you: </span></p>
<ul>
<li>have kidney problems. Your healthcare provider may give you a lower dose of VALCYTE, or check you more often if you take VALCYTE.</li>
<li>are receiving hemodialysis. </li>
<li>have blood cell problems.</li>
<li>are having radiation treatment.</li>
<li>have any other medical conditions.</li>
<li>are pregnant or plan to become pregnant. It is not known if VALCYTE causes <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in an unborn baby. <span class="Bold">Tell your healthcare provider right away if you become pregnant while taking VALCYTE. See <span class="Underline">"<a href="#important">What is the most important information I should know about VALCYTE?</a>"</span></span>
</li>
<li>are breastfeeding or plan to breastfeed. It is not known if VALCYTE passes into your breast milk. You should not breastfeed if you take VALCYTE. 							<ul class="Circle">
<li>You should not breastfeed if you have Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus (HIV-1) because of the risk of passing HIV-1 to your baby.</li>
<li>Talk to your healthcare provider about the best way to feed your baby. </li>
</ul>
</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins and herbal supplements. </p>
<p>VALCYTE and other medicines may affect each other and cause serious side effects. Keep a list of your medicines to show your healthcare provider and pharmacist. </p>
<ul>
<li>You can ask your healthcare provider or pharmacist for a list of medicines that interact with VALCYTE.</li>
<li>
<span class="Bold">Do not start taking a new medicine without telling your healthcare provider.</span> Your healthcare provider can tell you if it is safe to take VALCYTE with other medicines.</li>
</ul>
<p><span class="Bold">How should I take VALCYTE?</span></p>
<ul>
<li>Take VALCYTE exactly as your healthcare provider tells you. Your dose of VALCYTE will depend on your medical condition.</li>
<li>Adults should only take VALCYTE tablets. Children may take either VALCYTE tablets or oral solution. </li>
<li>Take VALCYTE with food.</li>
<li>Do not break or crush VALCYTE tablets. Avoid contact with your skin or eyes. If you come in contact with the contents of the tablet or oral solution, wash your skin well with soap and water or rinse your eyes well with plain water. </li>
<li>If your child is prescribed VALCYTE for oral solution, your pharmacist will give you dosing dispensers to measure your dose of VALCYTE for oral solution. To be sure you receive the prescribed dose, it is important to use the dispenser provided to you. Be sure to read, and that you understand, and follow the instructions below on how to take VALCYTE for oral solution and how to use the dispenser. Ask your pharmacist if you have any questions. If you lose or damage your dispensers and cannot use them, contact your pharmacist.</li>
<li>If you miss a dose of VALCYTE, take the missed dose as soon as you remember. Then, take the next dose at the usual scheduled time. However, if it is almost time for your next dose, <span class="Bold">do not take the missed dose.</span>
</li>
<li>Do not let your VALCYTE run out. The amount of virus in your blood may increase if your medicine is stopped, even for a short time.</li>
<li>If you take too much VALCYTE, call your healthcare provider or go to the nearest hospital emergency room right away. </li>
</ul>
<p>Talk to your healthcare provider, nurse or pharmacist if you have questions about your medicine.</p>
<p><span class="Bold">What should I avoid while taking VALCYTE?</span></p>
<ul><li>VALCYTE <span class="Bold">can cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, unsteady movements, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>. You should not drive a car or operate other dangerous machinery until you know how</span> VALCYTE <span class="Bold">affects you.</span>
</li></ul>
<p><span class="Bold">What are the possible side effects of VALCYTE?</span></p>
<p>VALCYTE may cause serious side effects, including:</p>
<p>See <span class="Underline">"<span class="Bold"><a href="#important">What is the most important information I should know about VALCYTE?</a></span>"</span></p>
<p><span class="Bold">Common side effects of VALCYTE in adults and children include:</span></p>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="60%">
<tbody class="Headless"><tr>
<td align="left"><ul>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li>shaky movements (<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>)</li>
</ul></td>
<td align="left"><ul>
<li>low white cell, red cell and platelet cell counts in blood tests </li>
<li>rejection of the transplanted organ (graft) </li>
</ul></td>
</tr></tbody>
</table>
<p><span class="Bold">Other common side effects in children include:</span></p>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="60%">
<tbody class="Headless"><tr>
<td align="left"><ul>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li>high blood pressure</li>
</ul></td>
<td align="left"><ul>
<li><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>  </li>
</ul></td>
</tr></tbody>
</table>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of VALCYTE. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How should I store VALCYTE?</span></p>
<ul>
<li>Store VALCYTE tablets at room temperature between 68°F to 77°F (20°C to 25°C).</li>
<li>Store VALCYTE for oral solution in the refrigerator between 36°F to 46°F (2°C to 8°C), for no longer than 49 days. Do not freeze.</li>
<li>Do not keep VALCYTE that is out of date or that you no longer need.</li>
<li><span class="Bold">Keep VALCYTE and all medicines out of the reach of children. </span></li>
</ul>
<p><span class="Bold">General information about the safe and effective use of VALCYTE</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VALCYTE for a condition for which it was not prescribed. Do not give VALCYTE to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about VALCYTE. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about VALCYTE that is written for health professionals. </p>
<p>For more information about VALCYTE go to www.VALCYTE.com or call 1-888-835-2555. </p>
<p><a name="end"></a><span class="Bold">What are the ingredients in VALCYTE? </span></p>
<p><span class="Bold">Active ingredient:</span> valganciclovir hydrochloride</p>
<p><span class="Bold">Inactive ingredients for Tablets:</span> microcrystalline cellulose, povidone K-30, crospovidone, and stearic acid. The film-coating applied to the tablets contains Opadry Pink<span class="Sup">®</span>.</p>
<p><span class="Bold">Inactive ingredients for Oral Solution:</span> sodium benzoate, fumaric acid, povidone K-30, sodium saccharin, mannitol and tutti-frutti flavoring</p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="section-18"></a><p></p>
<h1>Instructions for Use</h1>
<p class="First"><span class="Bold">VALCYTE (Val-site)<br>(valganciclovir hydrochloride)<br>for oral solution</span></p>
<p><span class="Bold">Important: </span></p>
<ul>
<li>Avoid contact with your skin or eyes. If you come in contact with the contents of the oral solution, wash your skin well with soap and water or rinse your eyes well with plain water. </li>
<li>Do not use VALCYTE for oral solution after the expiration date on the bottle.</li>
<li>Call your pharmacist if your oral dispenser is lost or damaged, and they will tell you how to continue to take your medicine. </li>
</ul>
<p><span class="Bold">How do I give VALCYTE for oral solution?</span></p>
<ul>
<li>Your pharmacist will mix VALCYTE for oral solution for you.</li>
<li>Be sure that you read, and that you understand and follow these instructions carefully to ensure proper dosing of the oral solution. To take a dose of VALCYTE for oral solution, you will need the bottle of medicine and an oral dispenser (see <span class="Bold"><a href="#fig1">Figure 1</a>)</span>.</li>
</ul>
<table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center"><span class="Bold">Figure 1</span></td></tr>
<tr><td align="center">
<a name="fig1"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dc548ff9-e8ea-4d6e-b9b4-e31f53ac4078&amp;name=valcyte-04.jpg">
</td></tr>
</tbody>
</table>
<ul>
<li>Shake closed bottle well for about 5 seconds before each use.</li>
<li>Remove the child-resistant bottle cap.</li>
<li>Before inserting the tip of the oral dispenser into bottle adapter, push the plunger completely down toward the tip of the oral dispenser.</li>
<li>Insert tip firmly into opening of the bottle adapter.</li>
<li>Turn the entire unit (bottle and oral dispenser) upside down (see <span class="Bold"><a href="#fig2">Figure 2</a></span>).<p class="First"><span class="Bold">Figure 2</span><br><a name="fig2"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dc548ff9-e8ea-4d6e-b9b4-e31f53ac4078&amp;name=valcyte-05.jpg"></p>
</li>
<li>Make sure the dosing dispenser stays connected to the bottle. Pull the plunger down slowly until the prescribed amount of medicine is withdrawn into the oral dispenser (see <span class="Bold"><a href="#fig3">Figure 3</a></span>).<p class="First"><span class="Bold">Figure 3</span><br><a name="fig3"></a><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dc548ff9-e8ea-4d6e-b9b4-e31f53ac4078&amp;name=valcyte-06.jpg"></p>
</li>
<li>Turn the entire unit right side up and remove the oral dispenser slowly from the bottle.</li>
<li>Give the dose of medicine directly into mouth and swallow. Do not mix with any liquid before giving the dose.</li>
<li>Close the bottle with child-resistant bottle cap after each use.</li>
<li>After taking your medicine, take apart (disassemble) the oral dispenser right away and rinse under running tap water. Then air dry before next use.</li>
</ul>
<p>This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration</p>
<p>VALCYTE is a registered trademark of Hoffmann-La Roche Inc.</p>
<p>Distributed by:</p>
<p><span class="Bold">Genentech USA, Inc.</span><br>A Member of the Roche Group<br>1 DNA Way<br>South San Francisco, CA 94080-4990</p>
<p>VECO_1079070_PI_2015_05_N</p>
<p>Revised:  April 2015</p>
<p>© 2015 Genentech, Inc. All rights reserved.</p>
<p>Representative sample of labeling (see the <a href="#S16">HOW SUPPLIED</a> section for complete listing):</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 450 mg Tablet Bottle Label</h1>
<p class="First">NDC 0004-0038-22</p>
<p><span class="Bold">Valcyte</span><span class="Sup">®</span><br>(valganciclovir HCl tablets)</p>
<p><span class="Bold">450 mg</span></p>
<p>equivalent to 450 mg valganciclovir</p>
<p><span class="Bold">DO NOT BREAK OR CRUSH TABLETS</span></p>
<p><span class="Bold">60 tablets<br>Rx only</span></p>
<p><span class="Bold">Genentech</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 450 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dc548ff9-e8ea-4d6e-b9b4-e31f53ac4078&amp;name=valcyte-07.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 50 mg/1 mL Bottle Carton</h1>
<p class="First">NDC 0004-0039-09</p>
<p><span class="Bold">Valcyte</span><span class="Sup">®</span><br>(valganciclovir<br>hydrochloride)<br>for oral solution</p>
<p><span class="Bold">50 mg/1 mL</span></p>
<p>Each mL of constituted<br>oral solution contains<br>50 mg valganciclovir<br>free base.</p>
<p><span class="Bold">100 mL (3.4 fl oz)<br>Rx only</span></p>
<p><span class="Bold">Genentech</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 mg/1 mL Bottle Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dc548ff9-e8ea-4d6e-b9b4-e31f53ac4078&amp;name=valcyte-08.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VALCYTE 		
					</strong><br><span class="contentTableReg">valganciclovir hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0004-0038</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>valganciclovir hydrochloride</strong> (ganciclovir) </td>
<td class="formItem">valganciclovir</td>
<td class="formItem">450 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone K29/32</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Convex oval) </td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">VGC;450</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0004-0038-22</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021304</td>
<td class="formItem">03/29/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VALCYTE 		
					</strong><br><span class="contentTableReg">valganciclovir hydrochloride powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0004-0039</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>valganciclovir hydrochloride</strong> (ganciclovir) </td>
<td class="formItem">valganciclovir</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium benzoate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>fumaric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone k30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>saccharin sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ACACIA</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (Colorless to brownish yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">TUTTI FRUTTI</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0004-0039-09</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 BOTTLE, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022257</td>
<td class="formItem">08/28/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Genentech, Inc.
							(080129000)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">F. Hoffmann-La Roche Ltd</td>
<td class="formItem"></td>
<td class="formItem">482242971</td>
<td class="formItem">API MANUFACTURE(0004-0038, 0004-0039)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>81a87b4e-2b48-419d-9e77-84ac0083bc39</div>
<div>Set id: dc548ff9-e8ea-4d6e-b9b4-e31f53ac4078</div>
<div>Version: 9</div>
<div>Effective Time: 20150430</div>
</div>
</div> <div class="DistributorName">Genentech, Inc.</div></p>
</body></html>
